The Children's Hospital of Philadelphia Foundation and Controlled Affiliates

Reports on Federal, State, and City Awards in Accordance with the OMB Uniform Guidance, the City of Philadelphia Subrecipient Audit Guide and New Jersey Department of the Treasury Circular Letter 15-08-OMB

June 30, 2021

EIN Numbers 23-1352166, 23-3036699, 22-2785804, 23-2589322, 23-2592835, 23-2665855

Page(s)

Part IV – Reports on Internal Control and Compliance

Part V –Findings and Questioned Costs

Report of Independent Auditors

To the Board of Trustees of
The Children's Hospital of Philadelphia Foundation and Controlled Affiliates

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of The Children's Hospital of Philadelphia Foundation and Controlled Affiliates (the "Enterprise"), which comprise the consolidated balance sheets as of June 30, 2021 and 2020, and the related consolidated statements of operations, of changes in net assets, and of cash flows for the years then ended and the related notes to the financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on the consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards,* issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the Enterprise's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Enterprise's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Children's Hospital of Philadelphia and Controlled Affiliates as of June 30, 2021 and 2020, and the results of its operations, its changes in net assets and its cash flows for

PricewaterhouseCoopers LLP, Two Commerce Square, Suite 1800, 2001 Market Street, Philadelphia, PA 19103-7042
T: (267) 330 3000, F: (267) 330 3300, www.pwc.com/us

the years then ended in accordance with accounting principles generally accepted in the United States of America.

Emphasis of Matter

As discussed in Note 6 to the consolidated financial statements, the Enterprise changed the manner in which it accounts for leases in 2021. Our opinion is not modified with respect to this matter.

Other Matters

Other Information (Consolidating Information)

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The consolidating information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The consolidating information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole. The consolidating information is presented for purposes of additional analysis of the consolidated financial statements rather than to present the financial position, results of operations and cash flows of the individual entities and is not a required part of the financial statements. Accordingly, we do not express an opinion on the financial position, results of operations and cash flows of the individual entities.

Other Information (Schedules of Expenditures of Federal and State Awards)

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards, schedule of expenditures of New Jersey state financial assistance awards, and the supplemental statements of program expenditures and program revenues of City of Philadelphia awards for the year ended June 30, 2021 are presented for purposes of additional analysis as required by Title 2 *U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, Audit Requirements for Federal Awards (Uniform Guidance), New Jersey Department of the Treasury State Grant Compliance Supplement, and the City of Philadelphia Subrecipient Audit Guide*, which incorporates the guidance from the Uniform Guidance and are not a required part of the consolidated financial statements. As described in Note 1 to the schedule of expenditures of federal awards, the accompanying schedule of expenditures of federal awards, schedule of expenditures of New Jersey state financial assistance awards, and supplemental statements of program expenditures and program revenues of City of Philadelphia awards were prepared on the cash basis, which is a comprehensive basis of accounting other than accounting principles generally accepted in the United States of America. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The schedule of expenditures of federal awards and the supplemental statements of program expenditures and program revenues of City of Philadelphia awards for the year ended June 30, 2021 have pwc

been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards, and supplemental statements of program expenditures and program revenues of City of Philadelphia awards are fairly stated, in all material respects on the basis of accounting described in Note 1, in relation to the consolidated financial statements as a whole.

The Schedule of Expenditures of New Jersey State Financial Assistance Awards for the year ended June 30, 2021 on page 62 has not been subjected to the auditing procedures applied in the audit of the consolidated financial statements and, accordingly, we do not express an opinion or provide any assurance on it.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated September 30, 2021 on our consideration of the Enterprise's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended June 30, 2021. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Enterprise's internal control over financial reporting and compliance.

PricewaterhouseCoopers LLP

Philadelphia, Pennsylvania

September 30, 2021

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Consolidated Balance Sheets
June 30, 2021 and 2020

ASSETS	June 30, 2021	June 30, 2020
Current assets		
Cash	$ 631,766,000	$ 715,362,000
Receivables for patient services	598,415,000	365,225,000
Current portion of pledges receivable, net	19,248,000	23,048,000
Due from third parties	29,329,000	16,265,000
Other receivables	96,391,000	98,250,000
Current portion of assets limited as to use	69,072,000	51,686,000
Supplies, drugs and prepaid expenses	47,563,000	59,074,000
Total current assets	1,491,784,000	1,328,910,000
Assets limited as to use		
Board designated	3,112,731,000	2,046,515,000
Restricted by donors	410,016,000	303,887,000
Trustee-held construction and debt service fund	40,968,000	23,571,000
Trustee-held for self-insurance and other	377,677,000	286,888,000
Noncurrent assets limited as to use	3,941,392,000	2,660,861,000
Investments	690,900,000	579,158,000
Land, buildings and equipment at cost, net	3,100,508,000	2,818,825,000
Operating lease right-of-use asset	193,258,000	-
Pledges receivable, net	70,958,000	66,025,000
Long-term notes receivable	20,910,000	20,910,000
Other long-term assets and receivables	30,202,000	25,838,000
Total assets	$9,539,912,000	$7,500,527,000
LIABILITIES AND NET ASSETS		
Current liabilities		
Current portion of long-term debt	$ 21,119,000	$ 19,581,000
Current portion of operating lease liabilities	21,801,000	-
Accounts payable and accrued expenses	648,684,000	497,195,000
Total current liabilities	691,604,000	516,776,000
Long-term debt, net	1,322,514,000	848,116,000
Other liabilities	312,863,000	289,213,000
Operating lease liabilities	171,457,000	-
Accrued pension cost	11,342,000	10,839,000
Total liabilities	2,509,780,000	1,664,944,000
NET ASSETS		
Without donor restriction	6,366,424,000	5,287,497,000
With donor restriction	663,708,000	548,086,000
Total net assets	7,030,132,000	5,835,583,000
Total liabilities and net assets	$9,539,912,000	$7,500,527,000

The accompanying notes are an integral part of these consolidated financial statements.

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Consolidated Statements of Operations
Years Ended June 30, 2021 and 2020

	June 30,	
	2021	2020
REVENUES AND OTHER SUPPORT		
Patient service revenue	$ 2,697,764,000	$ 2,533,001,000
Contributions	20,929,000	11,600,000
Research revenue	303,972,000	249,875,000
Other operating revenue and gains	203,475,000	143,918,000
CARES Act Funding	114,802,000	54,275,000
Total revenues and other support	3,340,942,000	2,992,669,000
EXPENSES		
Salaries, wages and professional fees	1,573,858,000	1,480,329,000
Employee benefits	398,576,000	364,798,000
Supplies	394,510,000	388,406,000
Purchased services and other expenses	491,661,000	470,631,000
Depreciation	245,689,000	233,492,000
Interest and amortization	21,907,000	21,285,000
Total expenses	3,126,201,000	2,958,941,000
Operating Income	214,741,000	33,728,000
Dividend and Interest income, net	26,763,000	37,151,000
Earnings allocations	(16,430,000)	(16,730,000)
Realized gains on investments	182,504,000	67,752,000
Change in unrealized gains/(loss) on investments	361,051,000	(25,711,000)
Sponsorship	1,092,000	(355,000)
Change in fair value of derivatives	14,000	17,000
Gains/(Loss) on alternative investments	305,011,000	(57,558,000)
Gains on equity method investments	-	204,083,000
Other components of net periodic benefit costs	(1,402,000)	(3,706,000)
Pension settlement	-	(161,154,000)
Non-controlling interest	(403,000)	(376,000)
Excess of revenue over expenses	1,072,941,000	77,141,000
Change in fair value of derivatives	4,111,000	616,000
Pension related changes other than net periodic benefit costs	(697,000)	196,904,000
Net assets released from restrictions for capital	3,102,000	1,639,000
External funding for capital	-	2,725,000
Transfer (to) / from net assets with donor restriction	(530,000)	(82,000)
Increase in net assets without donor restriction	$ 1,078,927,000	$ 278,943,000

The accompanying notes are an integral part of these consolidated financial statements.

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Consolidated Statements of Changes in Net Assets
Years Ended June 30, 2021 and 2020

	June 30,	
	2021	**2020**
NET ASSETS WITHOUT DONOR RESTRICTION		
Excess of revenues over expenses	$ 1,072,941,000	$ 77,141,000
Pension adjustment	(697,000)	196,904,000
Change in fair value of derivatives	4,111,000	616,000
Net assets released from restrictions for capital	3,102,000	1,639,000
External funding for capital	-	2,725,000
Transfer (to) / from net assets with donor restriction, net	(530,000)	(82,000)
Increase in net assets without donor restriction	1,078,927,000	278,943,000
NET ASSETS WITH DONOR RESTRICTION		
Contributions	67,921,000	75,489,000
Interest and dividend income	2,242,000	3,068,000
Realized gains on investments	16,984,000	5,549,000
Change in unrealized gains/(loss) on investments	64,961,000	(6,872,000)
Net assets released from restrictions for operations	(36,385,000)	(41,336,000)
Net assets released from restrictions for capital	(3,102,000)	(1,639,000)
Increase in value of perpetual trusts	2,471,000	82,000
Transfer (to) / from net assets without donor restriction, net	530,000	82,000
Increase in net assets with donor restriction	115,622,000	34,423,000
Increase in net assets	1,194,549,000	313,366,000
NET ASSETS		
Beginning of Year	5,835,583,000	5,522,217,000
End of Period	$ 7,030,132,000	$ 5,835,583,000

The accompanying notes are an integral part of these consolidated financial statements.

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Consolidated Statements of Cash Flows
Years Ended June 30, 2021 and 2020

	June 30,	
	2021	**2020**
CASH FLOWS FROM OPERATING ACTIVITIES		
Increase in net assets	$1,194,549,000	$313,366,000
Adjustments to reconcile increase in net assets to net cash provided by operating activities		
Depreciation and amortization	244,801,000	232,193,000
Contributions restricted for endowment and capital	(47,118,000)	(28,591,000)
Realized gains on investments	(199,488,000)	(73,301,000)
Change in unrealized (gains) losses on investments	(733,494,000)	90,058,000
Change in equity method (loss) / gain on sale of shares	-	(204,083,000)
Change in fair value of derivatives	(4,125,000)	(632,000)
Pension adjustment	697,000	32,044,000
Receivables for patient services	(233,190,000)	162,407,000
Other current assets	13,370,000	(75,679,000)
Pledges receivable	(1,133,000)	(4,068,000)
Other long term assets	(3,476,000)	(19,873,000)
Accounts payable and accrued expenses	173,129,000	16,712,000
Accrued pension cost	(194,000)	(68,577,000)
Amounts due from third parties, net	(13,064,000)	17,244,000
Other liabilities	195,107,000	23,460,000
Other bond related accounts	(3,265,000)	(1,166,000)
Net cash provided by operating activities	583,106,000	411,514,000
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of land, buildings and equipment	(716,344,000)	(377,546,000)
Purchase of investments	(2,149,430,000)	(1,844,873,000)
Sale of investments	1,697,696,000	1,630,452,000
Net cash used by investing activities	(1,168,078,000)	(591,967,000)
CASH FLOWS FROM FINANCING ACTIVITIES		
Repayment of long-term debt	(20,799,000)	(28,408,000)
Proceeds from new debt	500,000,000	-
Contributions restricted for endowment and capital	47,118,000	28,591,000
Net cash provided by financing activities	526,319,000	183,000
Net decrease in cash and restricted cash	(58,653,000)	(180,270,000)
Cash, cash equivalents and restricted cash		
Beginning of Year	857,898,000	1,102,256,000
End of Year	$799,245,000	$921,986,000
Supplemental disclosure of cash flow information		
Cash paid for interest, net of capitalized interest	$16,397,000	$20,855,000

The accompanying notes are an integral part of these consolidated financial statements.

1. Organization and Summary of Significant Accounting Policies

The Children's Hospital of Philadelphia Foundation (the "Foundation") and The Children's Hospital of Philadelphia ("CHOP") are Pennsylvania nonprofit tax-exempt corporations. The Foundation is the parent corporation of CHOP and raises charitable contributions to support the tax-exempt activities of CHOP. In July 2002, the Foundation and CHOP formed an "Obligated Group" with J.P. Morgan Trust Company as Trustee. Also included in the operating results of the Obligated Group are the following entities: CHOP Clinical Associates, Inc. ("Clinical Associates"), The Children's Hospital of Philadelphia Practice Association ("CHOPPA"), First Medical Insurance Company ("RRG"), Bache Lewis and Penrose LLC, 4865 Market Street Associates LP and 1700 Broad Street Inc.

CHOP was founded in 1855 and is the nation's first hospital dedicated exclusively to pediatrics. The hospital strives to be the world leader in the advancement of health care for children by integrating excellent patient care, innovative research and quality professional education into all its programs. CHOP is an integrated pediatric health care delivery system that provides quaternary and acute level pediatric services as well as emergency, primary, specialty, homecare and poison control care for children. CHOP has fostered some of the nation's pioneers in pediatric medicine and continues to be the premier training ground for future pediatric leaders. Its educational program includes one of the largest pediatric residency programs in the country. The hospital is also committed to researching and finding cures for chronic and fatal pediatric illnesses through its extensive research program.

CHOP is the controlling corporation of Children's Anesthesiology Associates, Ltd., Children's Health Care Associates, Inc., Children's Surgical Associates, Ltd., and Radiology Associates of Children's Hospital, Inc. (collectively, together with their New Jersey counterparts and their affiliates, the "Practice Plans"). The Practice Plans represent the physician service departments at CHOP in anesthesiology and critical care medicine, pediatrics, surgery and radiology, respectively. They provide and bill for medical professional clinical services performed at CHOP or in connection with CHOP programs, provide teaching services at CHOP and at the University of Pennsylvania School of Medicine, and engage in research activities at CHOP. The Practice Plans are not part of the Obligated Group and have no obligation with respect to the Obligated Group debt.

Clinical Associates is a New Jersey nonprofit corporation engaged in the practice of medicine in New Jersey exclusively for charitable, educational and scientific purposes by providing medical and closely allied professional services to the public, engaging in medical education and working to improve the welfare of children, all in support of CHOP. The sole member of Clinical Associates is a member of the medical staff of CHOP, who is licensed to practice medicine in New Jersey. Through an operating agreement between CHOP and Clinical Associates, CHOP provides funding for Clinical Associates' activities. In addition, through a services agreement, CHOP provides management services including billing for Clinical Associates' revenues and payment of all operating expenses. Reimbursement for management services is paid from Clinical Associates practice revenues.

CHOPPA was formed for the purposes of (a) billing for behavioral health services and (b) developing, supporting, and operating a University-affiliated, multi-disciplinary, academic pediatric group practice whose activities include (but are not limited to) the provision of clinical and clinical support services, the promotion of teaching, undergraduate, and post-graduate medical education, and research. CHOP is the sole member of CHOPPA.

RRG is a wholly owned risk retention group domiciled in Vermont and owned principally by CHOP with other tax-exempt CHOP affiliates owning the remaining interests.

Bache Lewis and Penrose LLC is a wholly owned holding company that holds assets to cover professional liability and workers compensation.

4865 Market Street Associates, L.P. is a limited partnership and a Qualified Active Low Income Community Business.

1700 Broad Street Inc. is a Pennsylvania non-profit corporation and is a corporation related to a project between the City of Philadelphia and CHOP to create a new South Philadelphia Family Care Center. The center includes a CHOP primary care practice, a city health center, a branch of the Free Library, and a recreational facility with a playground.

CHOP is the controlling corporation of PGH Development Corporation ("PGHDC"). PGHDC results are included in the consolidated financial statements. PGHDC is not part of the Obligated Group and has no obligation with respect to the Obligated Group debt.

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates are comprised of the Obligated Group, Practice Plans and PGHDC, which constitute the "Enterprise."

A summary of significant accounting policies observed by the Children's Hospital of Philadelphia Foundation and Controlled Affiliates is as follows:

Principles of Consolidation
The accompanying consolidated financial statements of the Enterprise include the accounts of the Foundation, CHOP, Clinical Associates, CHOPPA, RRG, Bache Lewis and Penrose, LLC, 4865 Market Street Associates LP, 1700 Broad Street Inc., PGHDC and the Practice Plans. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. All significant inter-company transactions and accounts have been eliminated.

Basis of Presentation
The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.

Financial Statement Presentation
The Enterprise has reported information regarding its financial position and operations according to its two classes of net assets: net assets without donor restriction and net assets with donor restriction.

Contributions received are recorded as with or without donor restriction, depending on the existence and/or nature of any donor restrictions. Net assets with donor restriction have been restricted by donors to a specific time period or purpose or have been restricted by donors to be maintained by the Enterprise in perpetuity. Net assets without donor restriction are those whose use has not been limited by a donor to a specific period of time or purpose or are donor-restricted contributions whose restrictions have been met within the same reporting period.

Prior Year Results
Certain prior year amounts have been reclassified to conform to current year presentation. This includes a reclassification of payor categories for patient revenue and concentration of credit risk.

Excess of Revenues over Expenses
The consolidated statements of operations include excess of revenues over expenses. Changes in net assets without donor restrictions which are excluded from excess of revenues over expenses, consistent with industry practice, include net assets released from restrictions for capital, external funding for capital, pension adjustments, transfers to / from net assets with restriction and the change in fair value of certain derivatives.

Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimates relate to implicit price concessions, contractual allowances, alternative investments and self-insurance reserves.

Cash
Cash includes cash amounts in non-interest-bearing and interest-bearing accounts. Cash equivalents consist of investments in highly liquid securities with a maturity of three months or less.

At June 30, 2021 and 2020, the Enterprise has cash and cash equivalents in major financial institutions which exceed Federal Depository Insurance limits. These financial institutions have strong credit ratings and management believes that credit risk related to these deposits is minimal.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheet that sum to amounts shown in the statement of cash flows.

	2021	2020
Cash	$ 631,766,000	$ 715,362,000
Cash equivalents and restricted cash included in other investments	167,479,000	142,536,000
	$ 799,245,000	$ 857,898,000

Amounts included in cash, cash equivalents, and restricted cash represent $631,766,000 of operating cash, $167,391,000 in our investment portfolio, $33,000 in funds limited to use for emergency construction costs for PGHDC and $55,000 in funds restricted for the payment of capital invoices for PGHDC.

Inventory Valuation
Inventories which are included in supplies, drugs and prepaid expenses on the balance sheet are generally stated at the lower of average cost or market value.

Assets Limited as to Use and Investments
Assets limited as to use include assets held by trustees under indenture agreements, and self-insurance agreements and designated assets set aside by the Board of Trustees (the "Board") for future capital improvements as well as research and clinical investments, over which the Board retains control and may at its discretion subsequently use for other purposes, and assets which have been set aside to meet restrictions by the donors. Amounts required to meet certain current liabilities of the Enterprise have been classified as current assets in the balance sheet at June 30, 2021 and 2020. The current portion of assets limited as to use is primarily for unfunded liabilities related to self-insurance.

Non-alternative investments and assets limited as to use are stated at fair value. The fair value of all debt and equity securities with a readily determinable fair value is based on quotations obtained from national securities exchanges. Investment income or loss (including realized gains and losses on investments, interest, and dividends) is included in excess of revenues over expenses. The Enterprise recognized an investment return, net of $804,801,000 and $225,717,000, for the years ended June 30, 2021 and 2020, respectively.

Alternative Investments are invested through private partnerships and primarily include private equity investments, real assets and hedge funds. These investments, with the exception of certain real assets in exchange traded funds, are not readily marketable, and are recorded at net asset value ("NAV") with the exception of other investments recorded using the equity method of accounting. The gains and losses on these investments are included in the excess of revenues over expenses. The Enterprise reviews and evaluates the values provided by the investment managers and agrees with the valuation methods and assumptions used in determining the value of the alternative investments. Because alternative investments are not readily marketable, their estimated value is subject to uncertainty and, therefore, may differ from the value that would have been used had a ready market for such investments existed. Such differences could be material. As of June 30, 2021 and 2020, the Enterprise had unfunded commitments relating to these net asset value investments of $381,747,000 and $312,844,000 respectively.

Investment securities, in general, are exposed to various risks, such as interest rate, credit and overall market volatility risks. Due to the level of risks associated with certain investment securities, it is reasonably possible that changes in the value of investments could occur in the near term and that such changes could materially affect the amounts reported in the accompanying consolidated balance sheets.

Accounts Receivable

Accounts receivable consist primarily of amounts owed by various governmental agencies, insurance companies and patients. This are represented on the balance sheet as receivables for patient services, pledge receivables, due from third party and other receivables. The Enterprise manages these receivables by regularly reviewing the accounts and contracts and by recording appropriate price concessions. The estimates for implicit price concessions are based upon management's assessment of historical write-offs and expected net collections, business and economic conditions, trends in federal, state and private employer health care coverage and other collection indicators. Management relies on the results of detailed reviews of historical write-offs and collections as the primary source of information in estimating the collectability of the accounts receivables. The Enterprise performs an analysis utilizing historical accounts receivable collection and write-off data. The Enterprise believes its quarterly updates to the estimated implicit price concession amounts at each of its hospital facilities provide reasonable valuation estimates of the Enterprise's revenues and accounts receivable.

Land, Buildings and Equipment

Land, buildings and equipment are recorded at cost for purchased items and at fair value for contributed items. Major renewals and improvements are capitalized while maintenance repairs are expensed when incurred. Depreciation is recognized over the estimated useful life of each class of depreciable asset and is computed using the straight-line method.

Other Long Term Assets and Receivables

Other long term assets and receivables include, but are not limited to, an estimated amount related to the Medical Care Availability and Reduction of Error Fund ("MCARE") recoveries. The MCARE recovery has an offsetting liability in Other Liabilities.

Accounting for Long-Lived Assets
The Enterprise assesses its assets for impairment whenever events or changes in circumstances indicate that the carrying amount of a respective asset that the Enterprise expects to hold and use may not be recoverable. In addition, the Enterprise periodically assesses the estimated useful lives as appropriate.

Accounts Payable and Accrued Expenses
Accounts payable and accrued expenses include, but are not limited to, trade accounts payables, accrued wages and related state and federal income taxes payable, accrued paid personal leave for employees and accrued employee healthcare related expenses.

Other Liabilities
Other liabilities include, but are not limited to, deferred revenue related to research activities, reserves for unfunded liabilities, reserves for MCARE liabilities, deferred employee compensation fair value of derivative financial instruments and other deferred liabilities.

Patient Service Revenue
Patient Service revenues are reported at the amount that reflects the consideration to which the Enterprise expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payors (including health insurers and government programs) and others. Generally, the Enterprise bills the patient and third-party payors several days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by the Enterprise. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected or actual charges. The Enterprise believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in our hospitals receiving inpatient acute care services. The Enterprise measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. Revenue for performance obligations satisfied at a point in time is recognized when goods or services are provided and the Enterprise does not believe it is required to provide additional goods or services to the patient.

Because all of its performance obligations relate to contracts with a duration of less than one year, the Enterprise has elected to apply the practical expedient provided in FASB ASC 606-10-50-14(a) and, therefore, is not required to disclose the aggregate amounts of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. These performance obligations are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

The Enterprise determines its transaction price by assessing the estimates of contractual adjustments and discounts based on contractual agreements, its discount policies, and historical experience. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. Estimates of contractual adjustments under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. The payment arrangements with third-party payers provide for payments to the Enterprise at amounts different from its established rates. Amounts the Enterprise receives for treatment of patients covered by governmental programs and third-party payors as well as directly from patients are subject to both explicit and implicit price concessions. The Enterprise estimates these price concessions using contractual agreements, discount policies, and historical experience. The Enterprise records price concessions in the period of service based on the analysis and consideration of these factors.

Patient service revenue, net of explicit and implicit price concessions, recognized in the period from these major payor sources, is as follows:

	2021			
	Inpatient	**Outpatient**	**Professional Fees**	**Total**
Blue Cross/Blue Shield	$ 415,849,000	$ 351,828,000	$ 324,473,000	$ 1,092,150,000
Medical Assistance	65,631,000	16,381,000	2,585,000	84,597,000
MA-Managed Care	333,011,000	175,233,000	114,057,000	622,301,000
Commercial	170,799,000	118,148,000	112,069,000	401,016,000
Aetna	150,415,000	126,298,000	94,652,000	371,365,000
Self Pay	1,121,000	1,702,000	5,673,000	8,496,000
Other	39,015,000	17,811,000	7,012,000	63,838,000
International	38,388,000	9,208,000	6,405,000	54,001,000
	$1,214,229,000	$ 816,609,000	$ 666,926,000	$ 2,697,764,000

	2020			
	Inpatient	**Outpatient**	**Professional Fees**	**Total**
Blue Cross/Blue Shield	$ 352,521,000	$ 316,156,000	$ 335,192,000	$ 1,003,869,000
Medical Assistance	54,426,000	27,286,000	(10,784,000)	70,928,000
MA-Managed Care	286,934,000	164,667,000	68,111,000	519,712,000
Commercial	158,683,000	115,522,000	112,076,000	386,281,000
Aetna	146,963,000	120,365,000	93,088,000	360,416,000
Self Pay	1,211,000	1,082,000	4,344,000	6,637,000
Other	51,780,000	15,343,000	2,405,000	69,528,000
International	57,864,000	37,277,000	20,489,000	115,630,000
	$ 1,110,382,000	$ 797,698,000	$ 624,921,000	$ 2,533,001,000

Generally, patients who are covered by third-party payers are responsible for related deductibles and coinsurance, which vary in amount. The Enterprise also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Enterprise estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. The Enterprise has elected the practical expedient allowed under FASB ASC 606-10-32-18 and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the Enterprises expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. Estimated implicit price concessions are recorded for all uninsured accounts, which includes uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage, regardless of the aging of those accounts. An increase in the level of uninsured patients to the Enterprise could have an unfavorable impact on the Enterprise's future operating results.

Charity Care

CHOP and Practice Plans provide care to patients who meet certain criteria under charity care policies without charge or at amounts less than their established charges. Because CHOP and Practice Plans do not pursue collection of amounts determined to qualify as charity care, they are not reported as revenue. The estimated cost of providing the charity services was $5,791,000 and $3,834,000 in 2021 and 2020, respectively. The estimated costs were based on a calculation which multiplied the percentage of operating expenses for the hospital to gross charity care charges. The percentage of cost to gross charges is calculated based on the total operating expenses for the hospital divided by gross patient service revenue for those facilities. An increase in the level of uninsured patients to our facilities and the resulting adverse trends in the implicit price concessions and charity care provided could have a material unfavorable impact on our future operating results.

Research Revenue

CHOP receives grant and contract revenue from governmental and private sources. In 2021 and 2020, grant and contract revenue earned totaled $304,094,000 and $263,933,000, respectively. CHOP recognizes revenue associated with the direct and the applicable indirect costs of federally sponsored programs as the related costs are incurred. For the majority of its grants, CHOP has determined that there is no exchange back to the granting authority. Therefore, CHOP accounts for these grants under the contribution model, which is outside the scope of ASC 606 and revenue is recognized as conditions are met. CHOP negotiates its federal indirect rate with its cognizant federal agency. Indirect costs recovered on federally-sponsored programs are generally based on predetermined reimbursement rates which are stated as a percentage and distributed based on the modified total direct costs incurred. Indirect costs recovered on all other grants and contracts are based on rates negotiated with the respective sponsors.

CHOP receives contributions in the form of conditional government grants. The grants are carried out for research activities that benefit the general public and not for the government's own use. The grants are considered conditional due to the need to first spend the awarded funds on qualifying expenses and a right of return exists for unexpended funds. The grants are reimbursed after the expenses have been incurred. CHOP has conditional contributions for which the conditions have not been met of $216,165,000 and $272,508,000 at June 30, 2021 and 2020, respectively.

Other Operating Revenue

Other operating revenue and gains consists of contributions released from restriction, specialty pharmacy revenue, one-time payment for payor contributions and other miscellaneous operating revenue. Other miscellaneous operating revenues are accounted for under ASC 606. CHOP has conditional contributions related to special purpose funds for which the conditions have not been met of $60,158,000 and $50,102,000 at June 30, 2021 and 2020, respectively.

CARES Act Stimulus Funding Revenue

In January 2020, the World Health Organization declared the novel strain of coronavirus ("COVID-19") a Public Health Emergency of International Concern. The COVID-19 pandemic has caused a disruption to our nation's healthcare system. Such disruption includes reduction in availability of staffing and reductions in the availability of personal protective equipment to prevent spread of the disease during patient treatment. "Stay at home" orders were issued for Pennsylvania on April 1, 2020 and for New Jersey in March 21, 2020. The stay at home orders for Pennsylvania and New Jersey were lifted in June 2020, with certain restrictions still in place. Healthcare organizations continue to respond to the COVID-19 crisis as the situation is dynamic and evolving on a daily basis. CHOP's response to the pandemic reflects this dynamic environment. CHOP's primary objective is to protect the health and safety of its employees and their families; patients, and their families; and the community at large. The pandemic caused a significant decrease in patient days, procedures and visits. With the restrictions on travel, out of area and international business has slowed significantly. While out of area patients have slowly begun to return to the main campus, international patients continue to be limited except in emergent cases, although CHOP continues to monitor potential international cases for when travel to the US becomes available. Emergency Department ("ED") visits were also significantly negatively impacted.

On March 27, 2020, the Federal Government passed the CARES Act (Coronavirus Aid, Relief, and Economic Stimulus Act), which allotted $175 billion dollars to healthcare providers and suppliers through Medicare reimbursements, grants and other direct federal payments for which CHOP and the Practice Plans qualified. CARES Act proceeds received from the Department of Health and Human Services as of June 30, 2020 were $54,275,000. In the year ended June 30, 2021, the Enterprise received additional CARES Act provider relief funding of $114,937,000. The Enterprise recognized $114,802,000 within CARES Act funding on the consolidated statement of operations. The remaining $135,000 is being held as deferred revenue on the other liabilities line on the balance sheet. The Enterprise recognized revenue related to the CARES Act provider relief funding based on information contained in laws and regulations, as well as interpretations issued by the Department of Health and Human Services (HHS), governing the funding that was publicly available at June 30, 2020 and 2021.

HHS requires the hospital and practice plans to identify healthcare related expenses attributable to coronavirus that another source has not reimbursed. If those expenses do not exceed the funding received the hospital and practice plans will need to demonstrate that the remaining provider relief funds were used for a negative change in calendar year 2020 patient care operating income compared to calendar year 2019. The same process was applied for calendar year 2021. HHS is entitled to recoup amounts in excess of the negative change in patient care operating income reported net of healthcare related expenses attributable to coronavirus.

Income Taxes

The Foundation, CHOP, Practice Plans and other corporations included in the consolidated financial statements (other than the LLC) are corporations that are recognized as exempt from federal income tax pursuant to Section 501(c)(3) of the Internal Revenue Code ("IRC"). The LLC is a disregarded entity and included in CHOP.

Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

Observable inputs reflect market data obtained from sources independent of the reporting entity and unobservable inputs reflect the entities own assumptions about how market participants would value an asset or liability based on the best information available.

Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy based on three levels of input, of which the first two are considered observable and the last unobservable, that may be used to measure fair value.

The following describes the hierarchy of inputs used to measure fair value and the primary valuation methodologies used by the Enterprise for financial instruments measured at fair value on a recurring basis. The three levels of inputs are as follows:

- Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities.
- Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the same term of the assets or liabilities.
- Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The carrying amounts reported on the consolidated balance sheets for cash, accounts receivable, accounts payable and accrued expenses approximates their fair value. The fair value of assets limited as to use and investments are included in Notes 4 and 5, respectively.

Recent Accounting Pronouncements

In February 2016, the FASB issued ASU-842, Leases. This standard requires lessees to recognize assets and liabilities for the rights and obligations created by leases with terms in excess of 12 months. The recognition, measurement, and presentation of expenses and cash flows arising from a lease will primarily depend on its classification as a finance or operating lease. The accounting by lessors remains largely unchanged. This standard was effective for fiscal years beginning after December 15, 2018 with an option to defer a year which CHOP elected. The Enterprise adopted this standard effective July 1, 2020 and utilized the modified retrospective transition method with no adjustments to comparative periods presented in the consolidated financial statements. All prior period results will continue to be presented under legacy guidance based on the accounting standards originally in effect for such period. The Enterprise elected the package of practical expedients available under the transition provisions of the new lease standard that allows the carry forward of historical conclusions on whether an existing contract is or contains a lease, the classification of existing leases and the treatment of direct costs. See Footnote 6 for further details.

In August 2018, the FASB issued ASU 2018-13, Disclosure Frameworks – Changes to the Disclosure Requirements for Fair Value Measurements, which modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019. The adoption did not have a material impact to the consolidated financial statements disclosures beginning in fiscal year 2021.

2. Net Assets

Net assets with donor restriction have restrictions based on the following: 1) restricted as to use by the Enterprise to a specific time period or purpose as directed by the donor or 2) the original value of gifts donated to the Enterprise through a permanent endowment, 3) the original value of subsequent gifts to the Enterprise through a permanent endowment, or 4) accumulations to the permanent endowment in accordance with applicable donor gift instruments.

The Enterprise follows the Pennsylvania Uniform Principal and Income Act ("Pennsylvania Act") to govern the investment, use and management of the endowment funds. The Pennsylvania Act allows a non-profit to elect to spend between 2% and 7% of the endowment market value, determined at least annually and averaged over a period of three or more preceding years. The Children's Hospital of Philadelphia board has elected a 5% spending rule.

The Enterprise considers the following factors in determining if donor-restricted endowment funds are accumulated or appropriated:

1) the duration and preservation of the fund
2) the purposes of the Enterprise's donor-restricted endowment funds
3) general economic conditions
4) effect of possible inflation or deflation
5) the expected total investment return and appreciation of investments
6) other resources of the Enterprise
7) investment policies of the Enterprise

The Enterprise's net assets with donor restriction consist of individual endowment accounts. Unless otherwise directed by the donor, gifts received for endowments are invested in accordance with the Enterprise's investment policy. Unless otherwise directed by the donor, the Enterprise annually appropriates a certain percentage of each endowment fund, which is then available for spending in accordance with the donor's intent. In order to preserve the real value of a donor's gift and to sustain funding consistent with donor intent, the annual appropriation rate is set to strike a reasonable balance between long-term objectives of preserving and growing each endowment fund for the future and providing stable, annual appropriations.

There are no donor restricted endowment funds where the market value is less than the historic gift amount ("underwater").

Board-designated funds are funds that are spent following board approval or have a specific board resolution.

The June 30, 2021 endowment net asset composition by type of fund consisted of the following:

	Without Restriction	With Restriction	Total
Donor-restricted funds	$ -	$ 370,277,000	$ 370,277,000
Investments	427,954,000	-	427,954,000
Board-designated funds	2,648,371,000	-	2,648,371,000
	$ 3,076,325,000	$ 370,277,000	$ 3,446,602,000

Changes in endowment net assets for the fiscal year ended June 30, 2021 consisted of the following:

	Without Restriction	With Restriction	Total
Endowment net assets, beginning of year	$ 2,327,438,000	$ 275,609,000	$ 2,603,047,000
Investment return:			
Investment income	18,541,000	2,229,000	20,770,000
Net appreciation (realized and unrealized)	741,859,000	80,804,000	822,663,000
Total investment return	760,400,000	83,033,000	843,433,000
Contributions	59,301,000	22,096,000	81,397,000
Transfers	39,847,000	241,000	40,088,000
Amounts appropriated for			-
expenditures	(110,661,000)	(10,702,000)	(121,363,000)
	$ 3,076,325,000	$ 370,277,000	$ 3,446,602,000

The June 30, 2020 endowment net asset composition by type of fund consisted of the following:

	Without Restriction	With Restriction	Total
Donor-restricted funds	$ -	$ 275,609,000	$ 275,609,000
Investments	346,571,000	-	346,571,000
Board-designated funds	1,980,867,000	-	1,980,867,000
	$ 2,327,438,000	$ 275,609,000	$ 2,603,047,000

Changes in endowment net assets for the fiscal year ended June 30, 2020 consisted of the following:

	Without Restriction	With Restriction	Total
Endowment net assets, beginning of year	$ 2,108,467,000	$ 263,474,000	$ 2,371,941,000
Investment return:			
Investment income	24,877,000	3,048,000	27,925,000
Net appreciation (realized and unrealized)	(17,878,000)	(1,362,000)	(19,240,000)
Total investment return	6,999,000	1,686,000	8,685,000
Contributions	246,332,000	20,500,000	266,832,000
Transfers	90,880,000	(122,000)	90,758,000
Amounts appropriated for expenditures	(125,240,000)	(9,929,000)	(135,169,000)
	$ 2,327,438,000	$ 275,609,000	$ 2,603,047,000

Net assets with donor restriction at June 30, 2021 and 2020 are available for the following purpose:

	2021	**2020**
Endowment	$ 370,038,000	$ 275,609,000
Special purpose, Pledges & Other	174,321,000	166,864,000
Research	88,699,000	80,634,000
Perpetual trusts	26,413,000	23,942,000
Capital improvements	4,237,000	1,037,000
	$ 663,708,000	$ 548,086,000

3. Pledges Receivable

Pledges receivable consists of private gifts and grants promised from individuals, corporations, foundations or other organizations.

Unconditional promises to give cash and other assets are reported at fair value at the date the promise is received. Restricted promises are reported as net assets with donor restrictions if they are received with donor stipulations that limit the use of the donated assets to a specific time period or purpose. The Enterprise is using an average discount rate of 3.82% for all pledge receivables.

Pledges receivable are expected to be realized in the following periods:

	2021	**2020**
Less than one year	$ 19,248,000	$ 23,048,000
One to five years	62,052,000	63,264,000
Thereafter	22,000,000	15,000,000
	103,300,000	101,312,000
Less: Present value discount	(11,919,000)	(11,084,000)
	91,381,000	90,228,000
Less: Allowance for uncollectible pledges	(1,175,000)	(1,155,000)
	90,206,000	89,073,000
Less: Current portion	(19,248,000)	(23,048,000)
	$ 70,958,000	$ 66,025,000

4. Assets Limited as to Use

Assets limited as to use are comprised of the following at June 30, 2021:

	Level 1	Level 2	Level 3	Net Asset Value Investments	Total
Board-designated					
Cash, cash equivalents and money market	$ 74,676,000	$ -	$ -	$ -	$ 74,676,000
Corporate and municipal bonds	-	710,356,000	42,619,000	-	752,975,000
Domestic and foreign equities	64,244,000	676,876,000	186,724,000	-	927,844,000
U.S. government securities	-	117,096,000	-	-	117,096,000
Private Equity, Real Assets & Hedge Funds	-	-	14,105,000	1,226,035,000	1,240,140,000
	138,920,000	1,504,328,000	243,448,000	1,226,035,000	3,112,731,000
Restricted by donors					
Cash, cash equivalents and money market	10,667,000	-	73,000	-	10,740,000
Corporate and municipal bonds	-	36,127,000	7,975,000	-	44,102,000
Domestic and foreign equities	9,197,000	96,895,000	30,399,000	-	136,491,000
U. S. government securities	-	16,762,000	-	-	16,762,000
Private Equity, Real Assets & Hedge Funds	-	-	-	175,508,000	175,508,000
Perpetual Trusts	-	-	26,413,000	-	26,413,000
	19,864,000	149,784,000	64,860,000	175,508,000	410,016,000
Held by trustee under debenture agreement					
Cash, cash equivalents and money market	40,968,000	-	-	-	40,968,000
	40,968,000	-	-	-	40,968,000
Self insurance					
Cash, cash equivalents and money market	23,954,000	-	-	-	23,954,000
Corporate and municipal bonds	-	72,928,000	5,130,000	-	78,058,000
Domestic and foreign equities	27,151,000	81,481,000	22,477,000	-	131,109,000
U. S. government securities	-	47,330,000	-	-	47,330,000
Private Equity, Real Assets & Hedge Funds	-	-	-	141,083,000	141,083,000
Other	-	-	25,215,000	-	25,215,000
	51,105,000	201,739,000	52,822,000	141,083,000	446,749,000
Less: Current portion	(20,893,000)	(48,179,000)	-	-	(69,072,000)
	30,212,000	153,560,000	52,822,000	141,083,000	377,677,000
	$ 229,964,000	$ 1,807,672,000	$ 361,130,000	$ 1,542,626,000	$ 3,941,392,000

Assets limited as to use are comprised of the following at June 30, 2020:

	Level 1	Level 2	Level 3	Net Asset Value Investments	Total
Board-designated					
Cash, cash equivalents and money market	$ 71,630,000	$ -	$ -	$ -	$ 71,630,000
Corporate and municipal bonds	-	361,610,000	41,146,000	-	402,756,000
Domestic and foreign equities	38,904,000	506,395,000	138,054,000	-	683,353,000
U.S. government securities	59,000	52,807,000	-	-	52,866,000
Private Equity, Real Assets & Hedge Funds	-	-	8,725,000	827,185,000	835,910,000
	110,593,000	920,812,000	187,925,000	827,185,000	2,046,515,000
Restricted by donors					
Cash, cash equivalents and money market	9,947,000	-	62,000	-	10,009,000
Corporate and municipal bonds	-	42,411,000	7,330,000	-	49,741,000
Domestic and foreign equities	5,415,000	70,488,000	22,353,000	-	98,256,000
U. S. government securities	8,000	7,351,000	-	-	7,359,000
Private Equity, Real Assets & Hedge Funds	-	-	-	115,141,000	115,141,000
Perpetual Trusts	-	-	23,381,000	-	23,381,000
	15,370,000	120,250,000	53,126,000	115,141,000	303,887,000
Held by trustee under debenture agreement					
Cash, cash equivalents and money market	23,571,000	-	-	-	23,571,000
	23,571,000	-	-	-	23,571,000
Self insurance					
Cash, cash equivalents and money market	20,311,000	-	-	-	20,311,000
Corporate and municipal bonds	153,000	82,783,000	4,533,000	-	87,469,000
Domestic and foreign equities	21,651,000	55,791,000	15,210,000	-	92,652,000
U. S. government securities	1,063,000	21,664,000	-	-	22,727,000
Private Equity, Real Assets & Hedge Funds	-	-	-	91,134,000	91,134,000
Other	-	-	24,281,000	-	24,281,000
	43,178,000	160,238,000	44,024,000	91,134,000	338,574,000
Less: Current portion	(16,251,000)	(35,435,000)	-	-	(51,686,000)
	26,927,000	124,803,000	44,024,000	91,134,000	286,888,000
	$ 176,461,000	$ 1,165,865,000	$ 285,075,000	$ 1,033,460,000	$ 2,660,861,000

Level 3 investments are largely comingled investment funds utilizing total market value for pricing. For level 3 investments with no observable inputs, reasonable attempts are made to obtain a price from an independent source. Real estate holdings are priced on relevant business days with an evaluation price based on the total value of the security for the share of the holdings. Net asset value investments relating to private equity, real estate and hedge funds are recorded at net asset value ("NAV") with the exception of Spark Therapeutics and other investments recorded using the equity method of accounting and are not required to be included as Level 1, 2 or 3.

The following table displays information by asset class for assets limited to use that are measured using NAV as a practical expedient as of June 30, 2021:

	Fair Value	Redemption Frequency	Redemption Notice Period	Unfunded Commitments
Equity Funds	$ -	Monthly/Quarterly	20-90 days	$ -
Hedge Funds	418,616,000	Monthly/Quarterly	20-90 days	-
Real Estate	85,206,000	Annually	Over 12 months	20,219,000
Venture Capital, Private Equity and Other	977,033,000	Annually	Over 12 months	317,996,000
	$1,480,855,000			$ 338,215,000

The following table displays information by asset class for assets limited to use that are measured using NAV as a practical expedient as of June 30, 2020:

	Fair Value	Redemption Frequency	Redemption Notice Period	Unfunded Commitments
Equity Funds	$ -	Monthly/Quarterly	20-90 days	$ -
Hedge Funds	310,163,000	Monthly/Quarterly	20-90 days	-
Real Estate	103,183,000	Annually	Over 12 months	34,715,000
Venture Capital, Private Equity and Other	620,114,000	Annually	Over 12 months	240,873,000
	$ 1,033,460,000			$ 275,588,000

Equity Funds: Commingled equity funds with a focus on energy and hard assets. Strategies involve Exchange Traded Funds that invest in both publicly traded companies as well as emerging markets.

Hedge Funds: Consists of private equity hedge funds. Strategies can be broadly diversified or narrowly focused and can range in terms of levels of net exposure.

Real Estate: Private equity partnerships with investments in real estate properties. Strategies focus in the United States but can cross geographic.

Venture Capital and Private Equity: Investments in private equity partnerships. Strategies can be broadly diversified or narrowly focused and can range in terms of levels of net exposure.

In 2013, CHOP established a for-profit company, Spark Therapeutics, Inc. ("Spark"). CHOP received its initial investment in common stock in consideration for the transfer of intellectual property rights and the assignment of contracts to Spark in connection with a technology assignment agreement. CHOP and Spark also entered into a research services agreement. CHOP is accounting for its investment in Spark under the equity method.

During fiscal year 2020, CHOP sold 1,954,957 shares of Spark Therapeutic. As a result of these sales, CHOP no longer has an ownership interest at June 30, 2020. CHOP recorded equity in losses of ($5,556,000) in 2020. The gain recorded for the year ended June 30, 2020 was $209,212,000.

The following table is a roll forward for the balance sheet amounts for financial instruments classified by the Enterprise within Level 3 of the fair value hierarchy defined above.

	Fair value 2020	Unrealized Gains (Losses)	Realized Gains (Losses)	Sales	Purchases	Fair value 2021
Cash, Cash Equivalents & Money Markets	$ 62,000	$ -	$ -	$ -	$ 11,000	$ 73,000
Corporate & Municipal Bonds	53,009,000	(5,338,000)	6,489,000	(28,342,000)	29,906,000	55,724,000
Domestic & Foreign Equities	175,617,000	56,039,000	9,661,000	(17,237,000)	15,520,000	239,600,000
Private Equity, Real Assets & Hedge Funds	8,725,000	266,663,000	131,035,000	(747,200,000)	354,882,000	14,105,000
Perpetual Trusts Held by 3rd Party	23,381,000	3,032,000	-	-	-	26,413,000
Other	24,281,000	934,000	-	-	-	25,215,000
	$ 285,075,000	$ 321,330,000	$ 147,185,000	$ (792,779,000)	$ 400,319,000	$ 361,130,000

	Fair value 2019	Unrealized Gains (Losses)	Realized Gains (Losses)	Sales	Purchases	Fair value 2020
Cash, Cash Equivalents & Money Markets	$ 83,000	$ -	$ -	$ (21,000)	$ -	$ 62,000
Corporate & Municipal Bonds	50,490,000	1,319,000	-	(177,000)	1,377,000	53,009,000
Domestic & Foreign Equities	182,271,000	(11,199,000)	1,333,000	(825,000)	4,037,000	175,617,000
Private Equity, Real Assets & Hedge Funds	1,924,000	(41,961,000)	9,414,000	(159,289,000)	198,637,000	8,725,000
Perpetual Trusts Held by 3rd Party	23,859,000	(478,000)	-	-	-	23,381,000
Other	24,916,000	(635,000)	-	-	-	24,281,000
	$ 283,543,000	$ (52,954,000)	$ 10,747,000	$ (160,312,000)	$ 204,051,000	$ 285,075,000

Included above, in restricted by donors are funds held in trust by others in perpetuity for the benefit of the Enterprise, which have been recorded in net assets with donor restriction at fair market value at $26,413,000 at June 30, 2021 and $23,381,000 at June 30, 2020.

5. Investments

Investments are comprised of the following at June 30, 2021:

	Level 1	Level 2	Level 3	Net Asset Value Investments	Total
Cash, cash equivalents and money market	$ 17,213,000	$ -	$ 20,000	$ -	$ 17,233,000
Corporate and municipal bonds	106,720,000	39,729,000	7,123,000	-	153,572,000
Domestic and foreign equities	171,208,000	106,558,000	30,462,000	-	308,228,000
U. S. government securities	-	18,434,000	-	-	18,434,000
Private Equity, Real Assets & Hedge Funds	-	-	-	193,260,000	193,260,000
Accrued Interest	173,000	-	-	-	173,000
	$ 295,314,000	$ 164,721,000	$ 37,605,000	$ 193,260,000	$ 690,900,000

Investments are comprised of the following at June 30, 2020:

	Level 1	Level 2	Level 3	Net Asset Value Investments	Total
Cash, cash equivalents and money market	$ 17,000,000	$ -	$ 14,000	$ -	$ 17,014,000
Corporate and municipal bonds	96,622,000	51,462,000	7,258,000	-	155,342,000
Domestic and foreign equities	148,169,000	85,531,000	24,111,000	-	257,811,000
U. S. government securities	10,000	8,919,000	-	-	8,929,000
Private Equity, Real Assets & Hedge Funds	-	-	350,000	139,712,000	140,062,000
Accrued Interest	-	-	-	-	-
	$ 261,801,000	$ 145,912,000	$ 31,733,000	$ 139,712,000	$ 579,158,000

Level 3 investments are largely comingled investment funds utilizing total market value for pricing. Alternative investments, except certain real assets, are accounted at net asset value or under the equity method of accounting and are not required to be included as Level 1, 2 or 3.

The following table displays information by investments that are measured using NAV as a practical expedient as of June 30, 2021:

	Fair Value	Redemption Frequency	Redemption Notice Period	Unfunded Commitments
Equity Funds	$ -	Monthly/Quarterly	20-90 days	$ -
Hedge Funds	52,156,000	Monthly/Quarterly	20-90 days	-
Real Estate	10,616,000	Annually	Over 12 months	2,519,000
Venture Capital, Private Equity and Other	121,731,000	Annually	Over 12 months	39,620,000
	$184,503,000			$ 42,139,000

The following table displays information by investments that are measured using NAV as a practical expedient as of June 30, 2020:

	Fair Value	Redemption Frequency	Redemption Notice Period	Unfunded Commitments
Equity Funds	$ -	Monthly/Quarterly	20-90 days	$ -
Hedge Funds	41,931,000	Monthly/Quarterly	20-90 days	-
Real Estate	13,949,000	Annually	Over 12 months	4,693,000
Venture Capital, Private Equity and Other	83,832,000	Annually	Over 12 months	32,563,000
	$ 139,712,000			$ 37,256,000

Equity Funds: Commingled equity funds with a focus on energy and hard assets. Strategies involve Exchange Traded Funds that invest in both publicly traded companies as well as emerging markets.

Hedge Funds: Consists of private equity hedge funds. Strategies can be broadly diversified or narrowly focused and can range in terms of levels of net exposure.

Real Estate: Private equity partnerships with investments in real estate properties. Strategies focus in the United States but can cross geographic.

Venture Capital and Private Equity: Investments in private equity partnerships. Strategies can be broadly diversified or narrowly focused and can range in terms of levels of net exposure.

The following table is a roll forward for the balance sheet amounts for financial instruments classified by the Enterprise within Level 3 of the fair value hierarchy defined above.

	Fair value 2020	Unrealized Gains (Losses)	Realized Gains (Losses)	Sales	Purchases	Fair value 2021
Cash, Cash Equivalents & Money Markets	$ 14,000	$ -	$ -	$ -	$ 6,000	$ 20,000
Corporate & Municipal Bonds	7,258,000	(594,000)	722,000	(3,155,000)	2,892,000	7,123,000
Domestic & Foreign Equities	24,111,000	6,238,000	1,075,000	(2,532,000)	1,570,000	30,462,000
Private Equity, Real Assets & Hedge Funds	350,000	29,684,000	14,586,000	(84,124,000)	39,504,000	-
	$ 31,733,000	$ 35,328,000	$ 16,383,000	$ (89,811,000)	$ 43,972,000	$ 37,605,000

	Fair value 2019	Unrealized Gains (Losses)	Realized Gains (Losses)	Sales	Purchases	Fair value 2020
Cash, Cash Equivalents & Money Markets	$ 15,000	$ -	$ -	$ (1,000)	$ -	$ 14,000
Corporate & Municipal Bonds	7,663,000	166,000	-	(624,000)	53,000	7,258,000
Domestic & Foreign Equities	27,770,000	(1,414,000)	168,000	(2,600,000)	187,000	24,111,000
Private Equity, Real Assets & Hedge Funds	350,000.00	(5,298,000)	1,188,000	(20,111,000)	24,221,000	350,000
	$ 35,798,000	$ (6,546,000)	$ 1,356,000	$ (23,336,000)	$ 24,461,000	$ 31,733,000

6. Land, Buildings, Equipment and Leases

Land, buildings and equipment and accumulated depreciation consist of the following at June 30:

	2021	2020
Assets		
Land	$ 76,013,000	$ 76,013,000
Land improvements	3,465,000	3,239,000
Buildings and building improvements	2,929,155,000	2,739,025,000
Fixed equipment	772,306,000	764,897,000
Major movable equipment	1,272,683,000	1,217,121,000
Construction in progress	646,771,000	392,994,000
	5,700,393,000	5,193,289,000
Accumulated depreciation		
Land improvements	(2,716,000)	(2,511,000)
Buildings and building improvements	(1,006,545,000)	(891,330,000)
Fixed equipment	(576,159,000)	(544,380,000)
Major movable equipment	(1,014,465,000)	(936,243,000)
	(2,599,885,000)	(2,374,464,000)
	$ 3,100,508,000	$ 2,818,825,000

The Enterprise capitalized $17,179,000 and $11,619,000 of interest expense during the years ended June 30, 2021 and 2020, respectively.

A component in the change year over year included in property, plant and equipment, net is change in non-cash additions of $4,286,000 and $25,874,000 for the years ended June 30, 2021 and 2020, respectively. The change in non-cash additions have been excluded from operating and investing activities in the statement of cash flow.

For financial reporting purposes, the Enterprise uses straight-line depreciation over the assets' estimated lives, which are as follows:

Land improvements	10-20 years
Buildings and building improvements	10-40 years
Fixed equipment	5-20 years
Major movable equipment	3-20 years

Construction-in-progress at June 30, 2021 relates to expansion projects at CHOP and information systems projects. The total estimated costs to complete the projects in construction-in-progress are approximately $977,570,000.

Leases

The Enterprise has operating leases related to real estate lease agreements for office space and clinical sites. Beginning July 1, 2020, the Enterprise adopted ASU 2016-02 using the effective method. At transition, lease right-of-use ("ROU") assets of $202,311,000, short term lease liabilities of $18,644,000 and long-term lease liability of $183,667,000 was recorded. At June 30, 2021, the Enterprise has lease ROU assets of $193,258,000 and lease liability of $193,258,000 reflected on the balance sheet which has a discount rate of 3.004% applied based on the Enterprise's incremental borrowing rate. The Enterprise election excludes non-lease components for real estate contracts, such as common area maintenance, in determining the ROU assets.

	2021
Weighted average remaining lease term:	
Operating leases	10.67 years
Weighted average discount rate:	
Operating leases	3.004%

The Enterprise is also a lessor of real estate under operating leases. Lease income for the year ended June 30, 2021 was $1,176,000, which is included in other operating revenue in the Consolidated Statements of Operations and Changes in Net Assets. Variable lease income included in the rent charges for maintenance costs is not material.

The Enterprise leases various facilities under operating leases expiring at various dates through 2027. Certain Practice Plans have office equipment under operating leases. Total rental expense in 2021 and 2020 for all operating leases was approximately $23,314,000 and $18,538,000, respectively, included in purchased services in the consolidated statement of operations.

The following is a schedule by year of future minimum lease payments under operating leases as of June 30, 2021, that have initial or remaining lease terms in excess of one year:

2022	$ 21,801,000
2023	22,571,000
2024	23,096,000
2025	23,136,000
2026 and beyond	126,539,000
Total lease payments	217,143,000
Less: Present value discount	(23,885,000)
Total lease obligation	193,258,000
Less: Current obligations	(21,801,000)
Long-term lease obligations	$ 171,457,000

Real estate leases may include options to renew that can extend the lease terms for an additional two to ten years. Some leases also include the options to terminate the lease early in line with the agreed upon contract terms. One lease includes an option for the right to purchase the premises with a closing to occur May 2034, the expiration of the 156th month following the commencement date. The Enterprise does not recognize these options as part of its ROU assets and lease liabilities because these options are evaluated at time of renewal.

Supplemental cash flow information related to leases for the period ended June 30 are as follows:

	2021
Cash paid for amounts included in the measurement of lease liabilities – operating cash flows from operating leases:	$ 23,314,000
Non-cash activity for the additions to the right of use assets obtained from operating leases:	$ 67,025,000

7. Long-Term Debt

Long-term debt consists of the following at June 30:

Bond	Fixed or Variable	Interest Payable	Effective Interest Rate	Maturity Date	Footnote	2021	2020
2002 A Bonds	Variable	Monthly	0.98%	7/1/2022	(a)	$4,900,000	$7,300,000
2002 B Bonds	Variable	Monthly	0.30%	7/1/2025	(a)	73,100,000	76,100,000
2005 A Bonds	Variable	Monthly	0.59%	2/15/2021	(b)	-	10,030,000
2011 A Bonds	Variable	Monthly	0.39%	7/1/2041	(c)	50,000,000	50,000,000
2011 B Bonds	Variable	Monthly	0.39%	7/1/2041	(c)	50,000,000	50,000,000
2011 C Bonds	Fixed	Semi-annually	4.13%	7/1/2041	(d)	81,465,000	83,690,000
2011 D Bonds	Fixed	Semi-annually	5.00%	7/1/2032	(e)	164,010,000	164,010,000
2014 A Bonds	Fixed	Semi-annually	4.47%	7/1/2044	(f)	190,420,000	190,420,000
2017 Bonds	Fixed	Semi-annually	4.36%	7/1/2037	(g)	174,815,000	176,280,000
2020 Bonds	Fixed	Semi-annually	1.94%	7/1/2050	(h)	500,000,000	-
Notes Payable 2014	Fixed	Annually	1.00%	12/31/2044	(i)	29,835,000	29,835,000
PIDC Loan	Fixed	Monthly	3.00%	5/1/2031	(j)	3,837,000	4,164,000
						1,322,382,000	841,829,000
Less: Current Portion						(21,119,000)	(19,581,000)
						1,301,263,000	822,248,000
Unamortized bond related liabilities						21,251,000	25,868,000
Total Long-Term Debt						$ 1,322,514,000	$ 848,116,000

Principal repayments as of June 30, 2021 on the debt are due as follows:

2022	$ 21,119,000
2023	21,745,000
2024	22,621,000
2025	23,533,000
2026	23,180,000
Thereafter	1,210,184,000
	$1,322,382,000

a. During July 2002, the Enterprise borrowed $309,300,000 under a Loan Agreement from the sale of tax-exempt Hospital Revenue Bonds (The Children's Hospital of Philadelphia Project), Series A, B, C, D, and E of 2002 (the "2002 Bonds") issued by the Enterprise and Higher Education Facilities Authority of Philadelphia (the "Authority"). The proceeds from the sale of the 2002 Bonds were deposited in escrow accounts and used to provide funds to (i) pay or reimburse CHOP for the costs of constructing new facilities (ii) advance refund the Hospital Revenue Bonds (CHOP) Series 1992A, 1992B and 1996A in the aggregate amount of $183,430,000 and the Hospital Revenue Bonds (CSH) Series 1992A and 1992B in the aggregate amount of $37,140,000, and (iii) fund debt service reserves and debt issuance costs pertaining to the 2002 Bonds.

   The 2002 Bonds were issued under a loan and trust agreement dated as of July 1, 2002 (the "Original Trust Agreement") among the Authority, J.P. Morgan Trust Company, National Association, as trustee, and the Foundation and CHOP. Under this agreement, the Foundation and CHOP (collectively considered the initial members of the Enterprise) are jointly and severally obligated to provide funds to service all outstanding debt of approximately $309,300,000 under the Master Indenture.

   Under the terms of the 2002 Bonds, the Enterprise pledged an interest in its gross revenues and is required to, among other things, meet defined debt service coverage and debt to capitalization ratios, maintain a minimum days cash on hand, and limit the amount of operating assets that may be disposed or transferred. The terms of the 2002 Bonds also specify conditions under which the members of the Enterprise may incur additional debt. Failure by the members of the Enterprise to observe certain covenants may result in the occurrence of an event of default, upon which the remaining obligations may be declared immediately due and payable. The Enterprise was in compliance with its covenants at June 30, 2021 and 2020.

b. During February 2005, the Enterprise borrowed $60,950,000 under a Loan Agreement from the sale of tax-exempt Hospital Revenue Bonds (The Children's Hospital of Philadelphia Project) Series A of 2005 (the "2005 A Bonds") issued by the Authority. The proceeds from the 2005 A Bonds were used to refinance $60,950,000 of the Series 1993 A Bonds. The 2005 A Bonds were issued under the Original Trust Agreement noted in (a) above, as supplemented by a second supplemental loan and trust agreement dated as of February 1, 2005 (the "Second Supplemental Trust Agreement" and together with the Trust Agreement). The 2005 A Bonds are payable, on a parity basis with the 2002 and 2003 Bonds. These bonds were paid off in February 2021.

c. During March 2011, the Enterprise borrowed $100,000,000 under a Loan Agreement from the sale of tax-exempt Hospital Revenue Bonds (The Children's Hospital of Philadelphia Project) Series 2011 A, and B (Series 2011 Bonds) issued by the Authority. The proceeds were used to finance the costs of a project consisting of: (A)(i) construction of a new, eight story ambulatory care center, a five-level underground parking garage for 1,500 cars and other improvements relating to the ambulatory care center; (ii) undertaking certain other miscellaneous capital projects, equipment purchases and campus renovation; (iii) reimbursing the Enterprise for certain costs heretofore incurred in connection with such projects; and (B) payment of bond issuance costs and expenses.

d. During October 2011, the Enterprise borrowed $96,785,000 under a Loan Agreement from the sale of tax-exempt Hospital Revenue Bonds (The Children's Hospital of Philadelphia Project) Series 2011 C, (Series 2011 Bonds) issued by the Authority. The proceeds were used to finance the costs of a project consisting of: (A)(i) construction of a new, eight story ambulatory care center, a five-level underground parking garage for 1,500 cars and other improvements relating to the ambulatory care center; (ii) undertaking certain other miscellaneous capital projects, equipment purchases and campus renovation; (iii) reimbursing the Enterprise for certain costs heretofore incurred in connection with such projects; and (B) payment of bond issuance costs and expenses.

e. During October 2011, the Enterprise borrowed $164,010,000 under a Loan Agreement from the sale of tax-exempt Hospital Revenue Bonds (The Children's Hospital of Philadelphia Project) Series 2011 D, (Series 2011 Bonds) issued by the Authority. The proceeds were used to (A) refund the Series 2008 A, B, and C bonds and (B) payment of bond issuance costs and expenses.

f. During September 2014, the Enterprise borrowed $190,420,000 under a Loan Agreement from the sale of tax-exempt Hospital Revenue Bonds (The Children's Hospital of Philadelphia Project) Series 2014 A, (Series 2014 Bonds) issued by the Philadelphia Authority for Industrial Development. The bonds were sold at a premium resulting in $200,000,000 in proceeds. The proceeds were used to finance the costs of a project consisting of: (A)(i) construction of a new, eight story ambulatory care center, a five-level underground parking garage for 1,500 cars and other improvements relating to the ambulatory care center; (ii) reimbursing the Enterprise for certain costs heretofore incurred in connection with such projects; and (B) payment of bond issuance costs and expenses.

g. During June 2017, the Enterprise borrowed $179,080,000 under a Loan Agreement from the sale of tax-exempt Hospital Revenue Bonds (The Children's Hospital of Philadelphia Project) Series 2017, (Series 2017 Bonds) issued by the Philadelphia Authority for Industrial Development. The bonds were sold at a premium resulting in $198,214,000 in proceeds. The net proceeds were paid to the Bond Trustee on behalf of CHOP and applied, together with other available funds of CHOP, to finance the costs of a project consisting of: (i) the current refunding of all of the outstanding Series A of 2007 Bonds and (ii) payment of bond issuance expenses and related costs and expenses.

h. During October 2020, the Enterprise borrowed $500,000,000 under a Loan Agreement from the Children's Hospital of Philadelphia Taxable Bonds, Series 2020, (Series 2020 Bonds) issued by the Bank of New York Mellon Trust Company, N.A... The bonds were sold at an underwriting discount of $3,285,000, resulting in net proceeds of $496,715,000. The proceeds of the Bonds will be used (1) for general corporate purposes of CHOP, including acquisition and construction of capital projects, and (2) to pay a portion of the costs of issuance of the Bonds.

i. During October 2014, the Enterprise entered into a transaction with Chase NMTC CHOP Investment Fund, LLC related to the 1700 Broad Street Family Care Center in South Philadelphia, Pennsylvania and expects to receive a net benefit of $9.0 million under a qualified New Markets Tax Credit Program ("NMTC"). The NMTC was provided for in the Community Renewal Tax Relief Act of 2000 (the "Act") and is intended to induce investment capital in under-served and impoverished areas of the United States. As a result of the transaction, the Enterprise has a receivable in the amount of $20,770,000 and a loan in the amount of $29,835,000. In 2020, the receivable and the loan were forgiven and CHOP recognized $9,065,000 of the net cash received in the year ended June 30, 2021.

j. The Enterprise also entered into a loan with Philadelphia Industrial Development Corporation ("PIDC") in the original principal amount of $8,279,000.

The series 2002, 2005, 2008 and 2011 A and B bonds are variable rate demand obligations which are payable on demand at the option of the bondholder. In connection with these bond offerings, CHOP entered into stand-by bond purchase agreements with various commercial banks which require the banks to purchase any bonds that are put by bondholders for payment. If the put bonds held by the banks are not remarketed after a 180 day period, the bonds will convert to term loans which are payable by CHOP in equal semi-annual installments over 5 years. Interest on the term loan is payable monthly at a rate of the greater of 9% or prime plus 2%. As of June 30, 2021, there were no bonds that were held by the banks under the terms of the stand-by purchase agreements.

Derivative Financial Instruments
In connection with the issuance of the 2002 Bonds, the Enterprise entered into two interest rate swap agreements on July 30, 2002 relating to Series A (the "2002A Swap") with expiration date of July 1, 2022. The 2002A Swap was entered into for the purpose of fixing interest rates on variable rate bonds, thus reducing exposures to interest rate fluctuations. The amount exchanged is based on the notional amount whereby the Enterprise pays the counterparty interest at a fixed rate and the counterparty pays the Enterprise at a variable rate based on the weekly Bond Market Association ("BMA") Index. The Enterprise has accounted for the 2002A Swap as a cash flow hedge with the change in valuation being accounted for as a component of the changes in net assets without donor restrictions.

In connection with the issuance of the 2005 Bonds, the Enterprise entered into an interest rate swap agreement on February 15, 2005 relating to the Series A (the "2005A Swap") with an expiration date of February 15, 2021. The swap was entered into for purposes of fixing interest rates on variable rate bonds, thus reducing exposures to interest rate fluctuations. The amount exchanged is based on the notional amount whereby the Enterprise pays the counterparty interest at a fixed rate and the counterparty pays the Enterprise at a variable rate based on the BMA Index. The Enterprise has accounted for the 2005A Swap as a cash flow hedge with the change in valuation being accounted for as a component of the changes in net assets without donor restrictions.

In March of 2020, the Enterprise entered two forward starting fixed rate swaps, each with an effective date of July 01, 2021. The first swap, 2011D had a notional amount of $165,670,000 set to expire on July 01, 2032 but was terminated on June 17, 2021. The second swap, 2011 C, has a notional amount of $79,940,000 and expires on July 01, 2041. As of June 30, 2021, the fair market value of the 2011C swaps was approximately $3,626,000.

The notional amounts and fair values, based on quoted market prices, of the Enterprise's derivative financial instruments are as follows at June 30:

	Notional	Balance Sheet (Other Liabilities)		Statement of Operations	
Interest Rate Swap		**2021**	**2020**	**2021**	**2020**
2002A Swap	$ 4,900,000	($104,000)	($302,000)	$ 198,000	$ 145,000
2005A Swap	10,030,000	-	(301,000)	301,000	488,000
2011C Swap	79,940,000	-	-	-	-
Totals	$94,870,000	($104,000)	($603,000)	$499,000	$633,000

Under these agreements, net interest expense of $519,000 and $1,138,000 relating to the derivative financial instruments was incurred for the years ended June 30, 2021 and 2020 respectively.

Interest rate swaps have been classified in Level 2 of the fair value hierarchy. For the over the counter derivatives that trade in liquid markets, such as interest rate swaps, model inputs (i.e. contractual terms, market prices, yield curves, credit curves and measures of volatility) can generally be verified and model selection does not involve significant management judgment.

8. Pension Plans

Through December 31, 1999, CHOP sponsored a defined benefit pension plan (the "Plan") that covered substantially all nonunion employees. The Plan called for benefits to be paid to eligible employees at retirement, based primarily upon years of service with CHOP and compensation. Contributions to the Plan reflected benefits attributed to employees' service to date, as well as service expected to be rendered in the future. Plan assets consisted primarily of common stock, investment-grade corporate bonds, and U.S. Government obligations.

The Plan sponsor voted to amend and restate the Plan effective January 1, 2000 to reflect the conversion of the Plan to a cash balance payment formula and the change in the Plan's name to The Children's Hospital of Philadelphia Pension Account Plan. Subject to certain grandfathering, the accrued benefit under the old plan was converted to the opening balance of the Pension Account Plan. The present value of the accrued benefit payable at age 65 was converted to a lump-sum using IRS required present value assumptions.

The Hospital's Boards of Trustees (the "Boards of Trustees") authorized the adoption of a noncontributory, defined benefit pension plan called the Pension Plan for Union-Represented Employees Hired before July 1, 2000 for the benefit of certain employees of CHOP as of June 30, 2000 who are covered under the collective bargaining agreement between CHOP and the National Union of Hospital and Health Care Employees, District 1199C. This plan excludes those employees of CHOP who had at least 15 years seniority with CHOP as of July 1, 2000, or who would be eligible to retire on an early or normal retirement date under the terms of the Pension Plan for Hospital and Health Care Employees, Philadelphia Vicinity (the "1199C Plan"), as in effect on June 1, 2000, on or before July 1, 2001, based on their anticipated service as of July 1, 2001 ("Grandfathered Union Employees"). These Grandfathered Union Employees remain in the 1199C plan.

The Boards of Trustees authorized the adoption of a noncontributory defined benefit pension plan with a cash balance payment formula called The Children's Hospital of Philadelphia Pension Plan for Union-Represented Employees Hired On or After July 1, 2000. This plan was similar to The Children's Hospital of Philadelphia Pension Account Plan as in effect at that time. This plan covers the employees under the collective bargaining agreement between CHOP and District 1199C hired on or after July 1, 2000.

On April 30, 2021, Children's Hospital of Philadelphia announced that The Children's Hospital of Philadelphia Pension Plan for Union-Represented Employees will be frozen as of December 31, 2021, and participants will not receive compensation credits or benefit accruals for periods beginning on or after January 1, 2022. This announcement resulted in a curtailment and remeasurement of net periodic pension cost for the Plan for the remainder of the 2021 fiscal year. There was no gain or loss due to this change. During the year ending June 30,2020, the Children's Hospital of Philadelphia Foundation loaned the Union Plan $12,000,000 which will be repaid with an exchange of alternative investments.

The 2021 and 2020 actuarially computed cost for the Plan, Pension Plan for Union Represented Employees hired before July 1, 2000 and Pension Plan for Union-Represented Employees hired after on or July 1, 2000 included the following components:

	2021	2020
Change in benefit obligation		
Benefit obligation at beginning of year	$ 110,475,000	$ 738,717,000
Service cost	4,403,000	6,320,000
Interest cost	3,564,000	7,560,000
Actuarial (gain) loss	528,000	(13,931,000)
Benefits paid	(1,364,000)	(5,094,000)
Administrative expenses paid	(535,000)	(2,879,000)
Curtailments	(7,571,000)	-
Settlements	-	(620,218,000)
Benefit obligation at end of year	109,500,000	110,475,000
Change in plan assets		
Fair value of plan assets at beginning of year	87,636,000	627,255,000
Actual return on plan assets (net expenses)	(5,579,000)	60,344,000
Employer contributions	6,250,000	28,227,000
Benefits paid	(1,364,000)	(5,093,000)
Administrative expenses paid	(535,000)	(2,879,000)
Settlements	-	(620,218,000)
Fair value of plan assets at end of year	86,408,000	87,636,000
Reconciliation of the funded status		
Funded status	(23,092,000)	(22,839,000)
Accrued pension cost	$ (23,092,000)	$ (22,839,000)

The accumulated benefit obligation for all defined benefit pension plans was $109,447,000 and $102,212,000 at June 30, 2021 and 2020, respectively.

	2021	2020
Components of net periodic benefit cost		
Service cost	$ 4,403,000	$ 6,320,000
Interest cost	3,564,000	7,560,000
Expected return on plan assets	(3,421,000)	(8,642,000)
Amortization of prior service cost	2,000	2,000
Amortization of net actuarial loss	1,257,000	2,232,000
Settlements	-	161,154,000
Net periodic benefit cost	$ 5,805,000	$168,626,000
Net (loss) / Gain	1,956,000	(33,516,000)
Amortization of prior service cost	(2,000)	(2,000)
Amortization of net loss	(1,257,000)	(2,232,000)
Settlements	-	(161,154,000)
Total recognized in net assets without donor restrictions	697,000	(196,904,000)
Total recognized in net periodic benefit cost and net assets without donor restrictions	$ 6,502,000	$ (28,278,000)

The estimated net loss that will be amortized from net assets without donor restrictions into net periodic benefit cost over the next fiscal year is $1,350,000. Amounts not yet recognized in net periodic benefit cost include $26,060,000 and $25,361,000 in actuarial loss and $0 and $2,000 in prior service cost for the periods ended June 30, 2021 and 2020, respectively.

	2021		2020
Weighted-average assumptions as of June 30			
Discount Rate (Pension Account Plan)	N/A		2.45%
Discount Rate (Union Represented Plan)	3.25%		3.75%
Rate of compensation increase (Pension Account Plan)	N/A		N/A
Rate of compensation increase (Union Represented Plan)	3.00%		3.00%
Weighted-average assumptions for net periodic benefit cost			
Discount rate	3.25% / 3.50%	(1)	3.25%
Expected return on plan assets	4.00% / 3.00%	(2)	3.80%
Rate of compensation (Pension Account Plan)	N/A		N/A
Rate of compensation (Union Represented Plan)	3.00%		3.00%

(1) Discount rate assumption was increased from 3.25% to 3.50% as of 4/30/2021, when fiscal 2021 expense was remeasured to reflect a 12/31/2021 freeze of future plan accruals.

(2) Expected long-term return on plan assets assumption was decreased from 4.00% to 3.00% as of 4/30/2021, when fiscal 2021 expense was remeasured to reflect a 12/31/2021 freeze of future plan accruals.

In 2020, CHOP adopted the Society of Actuaries Pri-2012 base table with generational projection using scale MP-2019 applied.

The average asset allocation of these pension plans at June 30, 2021 and 2020 by asset category are as follows:

	Percentage of Plan Assets 2021	Percentage of Plan Assets 2020
Government Securities	82%	84%
Alternative Investments	9%	9%
Cash	9%	7%
	100%	100%

The expected long-term rate of return for the U.S. plan assets is based on the expected return of each of the above categories, weighted based on the target allocations for each class. Equity securities are expected to return 10% on average over the long-term. Debt securities are expected to return 6% over the long term and real assets are expected to return 8% over the long term.

The majority of the Union Plan assets, approximately 82%, are invested in highly rated long-term Treasury securities to maintain liquidity and minimize permanent loss of capital due to increased volatility in other markets and impairments to the economy. Approximately 9% of plan assets are in cash, with the remainder of assets in alternative investments including private equity, real assets, and hedge funds that follow multiple different strategies.

Estimated future benefit payments

The following benefit payments which reflect expected future service, as appropriate, are expected to be paid:

2022	$ 2,018,000
2023	2,351,000
2024	2,689,000
2025	3,026,000
2026	3,377,000
2027 - 2031	21,846,000

Contributions

The Enterprise projects it will be required to make a pension plan contribution of approximately $6,250,000 to the Plan in 2022.

Fair Value

The following table sets forth by level within the fair value hierarchy, the Plan's assets at fair value as of June 30, 2021:

	Level 1	Level 2	Level 3	Net Asset Value Investments	Total
Cash	$ -	$ -	$ 8,816,000	$ -	$ 8,816,000
Debt	-	69,941,000	-	-	69,941,000
Equities	-	-	-	-	-
Alternative	-	-	-	7,651,000	7,651,000
Total	$ -	$ 69,941,000	$ 8,816,000	$ 7,651,000	$ 86,408,000

The following table sets forth by level within the fair value hierarchy, the Plan's assets at fair value as of June 30, 2020:

	Level 1	Level 2	Level 3	Net Asset Value Investments	Total
Cash	$ -	$ -	$ 1,959,000	$ -	$ 1,959,000
Debt	-	74,295,000	3,595,000	-	77,890,000
Equities	-	-	-	-	-
Alternative	-	-	-	7,787,000	7,787,000
Total	$ -	$ 74,295,000	$ 5,554,000	$ 7,787,000	$ 87,636,000

The following table sets forth a summary of changes in the fair value of the Plan's Level 3 investments for the years ended June 30, 2021 and 2020.

	Fair value 2020	Unrealized Gains (Losses)	Realized Gains (Losses)	Sales	Purchases	Fair value 2021
Cash	$ 1,959,000	$ -	$ -	$ -	$ 6,857,000	$ 8,816,000
Debt	-	-	-	-	-	-
Equity	-	-	-	-	-	-
	$ 1,959,000	$ -	$ -	$ -	$ 6,857,000	$ 8,816,000

	Fair value 2019	Unrealized Gains (Losses)	Realized Gains (Losses)	Sales	Purchases	Fair value 2020
Cash	$ 114,962,000	$ -	$ -	$ (125,138,000)	$ 12,135,000	$ 1,959,000
Debt	-	-	-	-	-	-
Equity	-	(34,000)	24,000	(33,000)	43,000	-
	$ 114,962,000	$ (34,000)		$ (125,171,000)	$ 12,178,000	$ 1,959,000

The Enterprise assets are managed by investment managers. Valuation techniques are utilized to maximize the use of observable inputs and minimize the use of unobservable inputs. The following is a description of the valuation methodologies used to measure fair value at June 30, 2021.

- Common stock is valued based on quoted market prices in the active markets on which the individual securities traded.
- Registered investment companies are valued at net asset value (NAV) of shares held by the Plan at year end.
- Alternative Investments are valued based upon the NAV of the fund held by the Plan at year end. The Plan considers valuations provided to it by the general partners of the funds. The values assigned to private equity funds are based upon assessment of each underlying investment, incorporating valuations that consider the evaluation of financing and sale transactions with third parties, expected cash flows and market-based information, including comparable transactions and performance multiples among other factors.

The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Plan believes it's valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

The Boards of Trustees authorized the adoption of a supplemental retirement plan, called The Children's Hospital of Philadelphia Retirement Savings Plan, which is a tax-deferred annuity plan under Section 403(b) of the IRC of 1986, as amended, for non-bargaining unit employees.

The Boards of Trustees authorized the adoption of a supplemental retirement plan, called The Children's Hospital of Philadelphia Retirement Savings Plan for Union-Represented Employees, which is a tax-deferred annuity plan under Section 403(b) of the IRC of 1986, as amended, for bargaining unit employees.

The Enterprise also has The Children's Hospital of Philadelphia Funded Retirement Savings Plan which is a defined contribution plan that operates under Section 401(a) of the Internal Revenue

Code (IRC) covering all employees of The Children's Hospital of Philadelphia (the Hospital) and any other subsidiaries as approved by the Board of Trustees of the Hospital (collectively, the Participating Employers), however, the Plan is sponsored by the Hospital. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (ERISA).

Total expenses under the supplemental retirement 403(b) plans were $23,944,000 and $23,333,000 for the periods ended June 30, 2021 and 2020. Total expenses under the funded retirement savings 401(a) plan were $44,200,000 and $41,000,000 for the periods ended June 30, 2021 and 2020.

9. Commitments and Contingencies and Other Transactions

Industry
The healthcare industry in general and the services that the Enterprise provides are subject to extensive federal and state laws and regulations. Additionally, a portion of the Enterprise's net revenue is from payments by government-sponsored healthcare programs, principally Medicaid, and is subject to audit and adjustments by applicable regulatory agencies. Failure to comply with any of these laws or regulations, the results of regulatory audits and adjustments, or changes in the amounts payable for the Enterprise's services under these programs, could have a material adverse effect on the Enterprise's financial position and results of operations.

Litigation
Although the Enterprise is party to certain claims and litigation, in the opinion of management, the final outcome of these are not reasonably expected to have a material adverse effect on their consolidated financial position or results of operations.

Professional Liability Insurance
By an agreement effective April 1, 1998 among CHOP and Children's Anesthesiology Associates, Ltd., Children's Health Care Associates, Inc., Children's Surgical Associates, Ltd., and Radiology Associates of Children's Hospital, Inc. (collectively, together with their New Jersey counterparts and their affiliates, the "Practice Plans"), and the Hospital's Departments of Pathology and Laboratory Medicine and Child and Adolescent Psychiatry (together with the Practice Plans, the "Departments"), CHOP and the Departments entered into a Joint Insurance Program (the "Joint Program"). Through June 30, 2001, the Joint Program was administered with the Departments participating with CHOP in its large deductible policies.

All claims with respect to occurrences beginning July 1, 2001 are insured through First Medical Insurance Company, a Risk Retention Group ("RRG"), domiciled in Vermont that was established by CHOP and certain of its tax-exempt affiliates, including the Practice Plans. Funding for indemnity, defense and other corporate expenses for the RRG are included in RRG accounts. The July 1, 2001 to July 1, 2002 policy period was novated from a large deductible commercial policy into the RRG effective July 2003.

CHOP includes the RRG's and other related investments, reserves, claim liabilities, and expenses for self-insured malpractice claims in the accompanying financial statements. Deposits to the RRG and other reserves are actuarially determined and represent estimates of funding necessary to cover the potential liability for professional malpractice claims and related legal fees and other expenses for CHOP and its affiliated health care provider entities and their covered physicians.

The estimate of the gross liability and corresponding receivable for unasserted claims arising from unreported incidents is based on analysis of historical claims data by an independent actuary, which is recorded utilizing a 3.0% to 4.5% discount rate at June 30, 2021 and June 30, 2020. Total liability under this program is approximately $283,629,000 and $239,958,000 included in other liabilities on the balance sheet, with a corresponding receivable included in other receivables of $29,740,000 and $24,218,000 at June 30, 2021 and 2020, respectively. CHOP also purchases catastrophic excess coverage.

CHOP and most of the physicians insured by the RRG are subject to Pennsylvania and/or New Jersey law requiring professional liability insurance. For policies written in 2002 and prior, the amount of required coverage pursuant to Pennsylvania law for physicians and nurse midwives was $1.2 million per incident/$3.6 million in the aggregate. For policies written subsequent to 2002, the required amount of coverage is $1 million per incident/$3 million in the aggregate.

The Medical Care Availability and Reduction of Error Fund ("MCARE")
The Medical Care Availability and Reduction of Error Fund ("MCARE Fund"), an agency fund of the Commonwealth of Pennsylvania, acts as a service agent to facilitate the payment of medical malpractice claims exceeding the primary layer of professional liability insurance carried by CHOP, and most of the physicians they insure. The MCARE Fund levies healthcare provider surcharges, as a percentage of joint underwriting association premiums for basic coverage, to pay claims and administrative expenses on behalf of MCARE Fund participants.

The actuarially computed liability to all health care providers (hospital, physicians and others) participating in the MCARE Fund at December 31, 2019 (the latest date for which such information is available) was $1.03 billion. CHOP, the Practice Plans, and the employed/insured physicians paid surcharge assessments during fiscal 2021 and 2020 totaling $5,564,000 and $5,500,000, respectively. No provision has been made for any MCARE Fund unfunded liabilities in the accompanying financial statements as CHOP's portion of the MCARE Fund unfunded liability cannot be reasonably estimated.

Workers' Compensation
The Enterprise is self-insured for workers' compensation claims. At June 30, 2021 and 2020, the Enterprise has an estimate of $4,930,000 and $4,896,000 respectively, included in accounts payable and accrued expenses to reserve for potential losses and paid expenses under the program. The discount rate used is 3%.

Other Transactions
The Practice Plans utilize the payroll accounting infrastructure of The University of Pennsylvania (UPenn) for certain Practice Plan personnel. Amounts due to these entities include in accounts payable and accrued expenses are as follows at June 30:

	2021	2020
UPenn	$35,809,000	$16,528,000

10. Concentrations of Credit Risk

The Enterprise grants credit without collateral to their patients, most of whom reside in the Delaware Valley, and are insured under third-party payor agreements. The mix of net receivables from patients and third-party payors at June 30 is as follows:

	2021	2020
Blue Cross/Blue Shield	29%	25%
Medical Assistance	6%	6%
MA-Managed Care	32%	31%
Commercial	14%	14%
Aetna	8%	9%
Self Pay	1%	2%
Other	2%	5%
International	8%	8%
	100%	100%

11. Functional Expenses

The Enterprise provides general and specialty health care services to pediatric patients. Costs by function are directly charged based on discrete cost centers. Expenses related to providing these services as of June 30 are as follows:

	June 30, 2021					
	Health Care Services	Research Services	Fundraising	Education	General and Administrative	Total
Salaries, wages and professional fees	$ 908,618,000	$181,374,000	$16,065,000	$ 32,777,000	$ 435,024,000	$1,573,858,000
Employee benefits	225,300,000	43,332,000	4,357,000	8,929,000	116,658,000	398,576,000
Supplies	331,403,000	36,875,000	372,000	276,000	25,584,000	394,510,000
Purchased services and other expenses	121,076,000	128,166,000	9,934,000	795,000	231,690,000	491,661,000
Depreciation	32,846,000	1,369,000	3,000	109,000	211,362,000	245,689,000
Interest and amortization	-	2,608,000	-	-	19,299,000	21,907,000
	$1,619,243,000	$393,724,000	$30,731,000	$ 42,886,000	$1,039,617,000	$3,126,201,000
Non-operating expenses:						
Investment Fees	-	-	6,515,000	-	959,000	7,474,000
Sponsorship	-	-	-	-	-	-
Other components of net periodic benefit costs	-	-	-	-	1,402,000	1,402,000
Pension settlement	-	-	-	-	-	-
	-	-	6,515,000	-	2,361,000	8,876,000
Total expenses	$1,619,243,000	$393,724,000	$37,246,000	$ 42,886,000	$1,041,978,000	$3,135,077,000

	June 30, 2020					
	Health Care Services	Research Services	Fundraising	Education	General and Administrative	Total
Operating expenses:						
Salaries, wages and professional fees	$1,039,254,000	$168,740,000	$15,168,000	$ 17,588,000	$ 239,579,000	$1,480,329,000
Employee benefits	241,674,000	41,496,000	3,844,000	2,862,000	74,922,000	364,798,000
Supplies	313,795,000	32,139,000	525,000	210,000	41,737,000	388,406,000
Purchased services and other expenses	89,427,000	151,510,000	11,082,000	734,000	217,877,000	470,630,000
Depreciation	21,967,000	41,303,000	3,000	56,000	170,164,000	233,493,000
Interest and amortization	-	3,839,000	-	-	17,446,000	21,285,000
	$1,706,117,000	$439,027,000	$30,622,000	$ 21,450,000	$ 761,725,000	$2,958,941,000
Non-operating expenses:						
Investment Fees	-	-	6,540,000	-	1,009,000	7,549,000
Sponsorship	-	-	-	-	355,000	355,000
Other components of net periodic benefit costs	-	-	-	-	3,706,000	3,706,000
Pension settlement	-	-	-	-	161,154,000	161,154,000
	-	-	6,540,000	-	166,224,000	172,764,000
Total expenses	$1,706,117,000	$439,027,000	$37,162,000	$ 21,450,000	$ 927,949,000	$3,131,705,000

12. Liquidity and Availability of Resources

Financial assets available within one year of the balance sheet date for general expenditures such as operating expenses and construction costs not financed with debt are as follows:

	2021	**2020**
Cash	$ 631,766,000	$ 715,362,000
Receivables from patient services	598,415,000	365,225,000
Due from third parties	29,329,000	16,265,000
Other receivables	96,391,000	98,250,000
Assets limited as to use	241,718,000	188,193,000
Investments (Level 1)	295,314,000	261,801,000
	$1,892,933,000	$1,645,096,000

Current financial assets not available for general use because of contractual or donor-imposed restrictions were $73,458,000 and $63,002,000 at June 30, 2021 and 2020, respectively. Amounts not available for general use include amounts set aside for scheduled principal payments, self-insurance funds, and time and purpose restricted assets. The Company strategically manages financial assets to ensure adequate liquidity for general expenditures and other obligations as they come due. In addition, the Company invests cash in excess of daily requirements in short-term investments. The Company maintains line of credit facilities with several banks to provide additional liquidity should unanticipated needs arise. In determining the amount of liquidity in board-designated endowment funds, management excludes amounts held in investments that may contain provisions prohibiting their redemption within one year and other investments for which redemption within one year may not be practical.

13. Subsequent Events

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates has evaluated and concluded that subsequent events are properly reflected in The Enterprise financial statements and notes as required by standard for accounting disclosure of subsequent events as of September 30, 2021, the original issuance date of the financial statements as of and for the year ended June 30, 2021.

In July 2021, the Enterprise borrowed $124,015,000 under a Loan Agreement from the sale of tax-exempt Hospital Revenue Bonds (The Children's Hospital of Philadelphia Project) Series A of 2021, (Series 2021 Bonds) issued by the Philadelphia Authority for Industrial Development. The bonds were sold at a premium resulting in $164,523,000 in proceeds which included $2,646,000 from the terminated swap. The Enterprise borrowed $241,485,000 under a Loan Agreement from the sale of tax-exempt Hospital Revenue Bonds (The Children's Hospital of Philadelphia Project) Series B of 2021, (Series 2021 Bonds) issued by the Philadelphia Authority for Industrial Development. The net proceeds of the sale are $241,485,000 with $945,000 of the sale proceeds being deposited with the Bond Trustee into the 2021B settlement account for the cost of issuance. The net proceeds to be received by the Authority from the sale of the 2021B Bonds, which are being issued simultaneously with the 2021A Bonds, will be applied to finance the costs of a project consisting of: (a) refunding of (i) the Hospitals Authority's $61,400,000 aggregate principal amount of Hospital Revenue Bonds (The Children's Hospital of Philadelphia Project) Series A and B of 2002; (ii) the Hospitals Authority's $100,000,000 aggregate principal amount of Hospital Revenue Bonds (The Children's Hospital of Philadelphia Project) Series A and B of 2011; and (iii) the Hospitals Authority's $79,140,000 aggregate principal amount of Hospital Revenue Bonds (The Children's Hospital of Philadelphia Project) Series C of 2011; and (b) paying the issuance costs of 2021B Bonds.

Supplemental Consolidating Schedules

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Supplemental Consolidating Balance Sheets
June 30, 2021

(in thousands of dollars)

ASSETS	Obligated Group	Practice Groups	PGHDC	Total Eliminations	Total Consolidated
Current assets					
Cash and cash equivalents	$ 469,030,000	$ 162,736,000	$ -	$ -	$ 631,766,000
Receivables for patient services	529,178,000	69,237,000	-	-	598,415,000
Current portion of pledges receivable	21,173,000	-	-	(1,925,000)	19,248,000
Due from third parties	29,329,000	-	-	-	29,329,000
Other receivables	158,731,000	61,390,000	466,000	(124,196,000)	96,391,000
Current portion of assets limited as to use	69,072,000	-	-	-	69,072,000
Supplies, drugs and prepaid expenses	47,329,000	223,000	11,000	-	47,563,000
Total current assets	1,323,842,000	293,586,000	477,000	(126,121,000)	1,491,784,000
Assets limited as to use					
Board designated	3,112,731,000	-	-	-	3,112,731,000
Restricted by donors	410,016,000	-	-	-	410,016,000
Trustee-held construction and debt service fund	40,880,000	-	88,000	-	40,968,000
Trustee-held for self-insurance and other	377,677,000	-	-	-	377,677,000
Noncurrent assets limited as to use	3,941,304,000	-	88,000	-	3,941,392,000
Investments	417,455,000	273,445,000	-	-	690,900,000
Land, buildings and equipment at cost, net	3,091,662,000	760,000	8,086,000	-	3,100,508,000
Operating lease right-to-use assets	193,258,000				193,258,000
Pledges receivable, net	72,254,000	-	-	(1,296,000)	70,958,000
Long-term notes receivable	20,910,000	-	-	-	20,910,000
Other long-term assets and receivables	30,202,000	-	-	-	30,202,000
Total assets	$9,090,887,000	$567,791,000	$8,651,000	($127,417,000)	$9,539,912,000
LIABILITIES AND NET ASSETS					
Current liabilities					
Current portion of long-term debt	$ 21,119,000	$ -	$ -	$ -	$ 21,119,000
Current portion of operating lease liability	21,801,000				21,801,000
Accounts payable and accrued expenses	638,373,000	134,163,000	344,000	(124,196,000)	648,684,000
Current portion of pledges payable	-	1,925,000	-	(1,925,000)	-
Total current liabilities	681,293,000	136,088,000	344,000	(126,121,000)	691,604,000
Long-term debt	1,322,514,000	-	-	-	1,322,514,000
Other liabilities	312,727,000	136,000	-	-	312,863,000
Operating lease liability	171,457,000				171,457,000
Accrued pension cost	11,342,000	-	-	-	11,342,000
Pledges payable, less current portion	-	1,296,000	-	(1,296,000)	-
Total liabilities	2,499,333,000	137,520,000	344,000	(127,417,000)	2,509,780,000
NET ASSETS					
Without donor restriction	5,891,014,000	430,271,000	4,057,000	41,082,000	6,366,424,000
With donor restriction	700,540,000	-	4,250,000	(41,082,000)	663,708,000
Total net assets	6,591,554,000	430,271,000	8,307,000	-	7,030,132,000
Total liabilities and net assets	$ 9,090,887,000	$ 567,791,000	$8,651,000	($127,417,000)	$ 9,539,912,000

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Supplemental Consolidating Statements of Operations
Year Ended June 30, 2021

(in thousands of dollars)

	Obligated Group	Practice Groups	PGHDC	Total Eliminations	Total Consolidated
REVENUES AND OTHER SUPPORT					
Patient service revenue	$2,186,694,000	$511,070,000	$ -	$ -	$ 2,697,764,000
Contributions	18,729,000	2,200,000	-	-	20,929,000
Research revenue	303,972,000	25,565,000	-	(25,565,000)	303,972,000
Other operating revenue	216,571,000	37,782,000	833,000	(51,711,000)	203,475,000
CARES Act Funding	105,172,000	9,630,000	-	-	114,802,000
Total revenues and other support	2,831,138,000	586,247,000	833,000	(77,276,000)	3,340,942,000
EXPENSES					
Salaries, wages and professional fees	1,190,175,000	384,699,000	-	(1,016,000)	1,573,858,000
Employee benefits	325,734,000	74,234,000	-	(1,392,000)	398,576,000
Supplies	387,213,000	7,297,000	-	-	394,510,000
Purchased services and other expenses	470,382,000	58,834,000	834,000	(38,389,000)	491,661,000
Depreciation	244,914,000	229,000	546,000	-	245,689,000
Interest and amortization	21,907,000	-	-	-	21,907,000
Total expenses	2,640,325,000	525,293,000	1,380,000	(40,797,000)	3,126,201,000
Operating Income	190,813,000	60,954,000	(547,000)	(36,479,000)	214,741,000
Dividend and interest income, net	23,725,000	3,038,000	-	-	26,763,000
Earnings allocation	(53,311,000)	-	-	36,881,000	(16,430,000)
Realized gains on investments	159,061,000	23,443,000	-	-	182,504,000
Changes in unrealized gains on investments	331,374,000	29,677,000	-	-	361,051,000
Sponsorship	58,326,000	(59,370,000)	-	2,136,000	1,092,000
Change in fair value of derivatives	14,000	-	-	-	14,000
Gains/(Loss) on alternative investments	305,011,000	-	-	-	305,011,000
Other components of net periodic benefit costs	(1,402,000)	-	-	-	(1,402,000)
Minority interest	-	-	-	(403,000)	(403,000)
Excess of revenue over expenses	1,013,611,000	57,742,000	(547,000)	2,135,000	1,072,941,000
Pension adjustment	(697,000)	-	-	-	(697,000)
Change in fair value of derivatives	4,111,000	-	-	-	4,111,000
Net assets released from restrictions for capital	3,102,000	-	-	-	3,102,000
Transfer to/from temporarily restricted net assets	(530,000)	-	-	-	(530,000)
Increase in net assets without donor restriction	$1,019,597,000	$57,742,000	($547,000)	$2,135,000	$1,078,927,000

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Supplemental Consolidating Statements of Changes in Net Assets
Year Ended June 30, 2021

(in thousands of dollars)

	Obligated Group	Practice Groups	PGHDC	Total Eliminations	Total Consolidated
NET ASSETS WITHOUT DONOR RESTRICTION					
Excess of revenues over expenses	$1,013,611,000	$57,742,000	($547,000)	$2,135,000	$1,072,941,000
Pension adjustment	(697,000)	-	-	-	(697,000)
Change in fair value of derivatives	4,111,000	-	-	-	4,111,000
Net assets released from restrictions for capital	3,102,000	-	-	-	3,102,000
Transfer from net assets with donor restrictions	(530,000)	-	-	-	(530,000)
Increase in net assets without donor restriction	1,019,597,000	57,742,000	(547,000)	2,135,000	1,078,927,000
NET ASSETS WITH DONOR RESTRICTION					
Contributions	70,056,000	-	-	(2,135,000)	67,921,000
Interest and dividend income	2,242,000	-	-	-	2,242,000
Realized gains on investments	16,984,000	-	-	-	16,984,000
Change in unrealized gains on investments	64,961,000	-	-	-	64,961,000
Net assets released from restrictions for operations	(36,385,000)	-	-	-	(36,385,000)
Net assets released from restrictions for capital	(3,102,000)	-	-	-	(3,102,000)
Adjustment to perpetual trusts	2,471,000	-	-	-	2,471,000
Transfer from net assets without donor restrictions	530,000	-	-	-	530,000
Increase in net assets with donor restriction	117,757,000	-	-	(2,135,000)	115,622,000
Increase in Net Assets	1,137,354,000	57,742,000	(547,000)	-	1,194,549,000
NET ASSETS					
Beginning of Year	5,454,200,000	372,529,000	8,854,000	-	5,835,583,000
End of Period	$6,591,554,000	$430,271,000	$8,307,000	-	$7,030,132,000

Schedules of Expenditures of Federal and State Awards

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Schedule of Expenditures of Federal Awards
Fiscal Year Ended June 30, 2021

Grantor Agency and Department	Assistance Listing Number	Pass-Through Entity	Pass-Through ID Numbers	Total Expenditures ($)	Amount Provided To Subrecipients ($)
Federal Awards:					
Research and Development Cluster					
U.S. Department of Health and Human Services					
Center for Disease Control					
Pass Through:					
Injury Prevention and Control Research and State and Community Based Programs	93.136	Minnesota HealthSolutions Corp	R44CE002753	63,308	-
Injury Prevention and Control Research and State and Community Based Programs	93.136	City of Philadelphia	CDC-RFA-CE19-1904	250,000	-
Cooperative Agreement Title: Strengthening Public Health Systems and Services	93.421	Task Force for Global Health	NU38OT00316	95,733	-
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	American Thrombosis&Hemophilia Inc	U27DD001155	252,902	196,149
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	American Thrombosis&Hemophilia Inc	NU27DD000020-01	205,440	118,060
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	University of Pennsylvania	U54CK000485	50,580	-
Pandemic Influenza Inpatient Renewal	93.RD	Abt Associates, Inc	93.HHSD20002013M53890B	5,999	-
Total Center for Disease Control and Prevention - Pass Through				923,962	314,210
Total Center for Disease Control				**923,962**	**314,210**
National Institutes of Health					
Direct Grants and Contracts:					
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353			7,646,145	3,553,809
Aging Research	93.866			1,133,413	104,485
Allergy, Immunology, and Transplantation Research	93.855			10,041,193	1,411,847
Arthritis, Musculoskeletal, and Skin Diseases Research	93.846			3,834,012	626,173
Assistance Programs for Chronic Disease Prevention and Control	93.945			95,960	-
Biomedical Research and Research Training	93.859			3,783,460	-
Blood Diseases and Resources Research	93.839			7,034,258	1,389,969
Cancer Biology Research	93.396			2,673,443	73,390
Cancer Cause and Prevention Research	93.393			762,357	325
Cancer Control	93.399			3,780,232	3,293,215
Cancer Detection and Prevention Research	93.394			809,242	486,991
Cancer Research Manpower	93.398			819,367	-
Cancer Treatment Research	93.395			26,585,035	22,564,830
Child Health and Human Development Extramural Research	93.865			11,690,107	2,480,858
Diabetes, Endocrinology, and Metabolism Research	93.847			15,977,306	3,139,073
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286			700,206	232,156
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853			10,399,642	1,359,166
Cardiovascular Diseases Research	93.837			18,870,720	7,634,618
Human Genome Research	93.172			1,903,672	191,475
Lung Diseases Research	93.838			3,261,760	182,315
Mental Health Research Grants	93.242			6,322,365	134,818
Mental and Behavioral Health Education and Training Grants	93.732			201,587	-
Minority Health and Health Disparities Research	93.307			703,317	94,895
National Center for Advancing Translational Sciences	93.350			1,212,034	581,941
National Center on Sleep Disorders Research	93.233			1,814,493	835,599
National Research Service Awards Health Services Research Training	93.225			576,799	333,786
Nursing Research	93.361			1,850,209	623,507
Oral Diseases and Disorders Research	93.121			139,341	-
Research Infrastructure Programs	93.351			1,731,367	-
Research Related to Deafness and Communication Disorders	93.173			327,962	25,870
Research and Training in Complementary and Integrative Health	93.213			128,554	-
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243			473,844	166,444
Targeted Clinical Trials to Reduce the Risk of Antimicrobial Resistance	93.RD			48,355	20,932
Targeted Clinical Research to Address Select-Viral Infections	93.RD			763,244	564,126
Trans-NIH Research Support	93.310			4,103,319	1,087,847
Vision Research	93.867			3,168,309	1,762,179
Total National Institutes of Health - Direct				155,366,626	54,956,637

The accompanying notes are an integral part of these financial statements.

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2021

Grantor Agency and Department	Assistance Listing Number	Pass-Through Entity	Pass-Through ID Numbers	Total Expenditures ($)	Amount Provided To Subrecipients ($)
Research and Development Cluster, continued					
Pass Through:					
Child Health and Human Development Extramural Research	93.865	Albert Einstein College of Med	P01HD070454	508,169	71,797
Cardiovascular Diseases Research	93.837	American Academy of Pediatrics	R01HL128231	18,250	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	AmideBio LLC	R34DK111304	313	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	AmideBio LLC	R44DK111304	74,243	-
Lung Diseases Research	93.838	Ann & Robert Lurie HospChicago	R34HL153474	12,020	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Ann & Robert Lurie HospChicago	U34DK115355	8,824	-
Child Health and Human Development Extramural Research	93.865	Ann & Robert Lurie HospChicago	R21HD096402	1,611	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Avanti Biosciences	R43DK115229	3,302	-
Child Health and Human Development Extramural Research	93.865	Baylor University	R01HD101326	20,579	-
Mental Health Research Grants	93.242	Boston University Medical Campus	R01MH104355	36,563	-
Human Genome Research	93.172	Brigham & Women's Hospital	U41HG006834	15,472	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Brigham & Women's Hospital	R01NS10007	54,446	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brown University	R01AR071382	133,922	-
Aging Research	93.866	Brown University	R01AG065722	91,169	-
Cancer Treatment Research	93.395	Children's Hosp of Los Angeles	P01CA217959	48,542	-
Cancer Treatment Research	93.395	Children's Hosp of Los Angeles	R01CA181050	8,203	-
Human Genome Research	93.172	Children's Hospital Boston	R01HG010004	8,014	-
Mental Health Research Grants	93.242	Children's Hospital Boston	U01MH119690	387,433	-
Alcohol Research Programs	93.273	Children's Hospital Boston	R01AA027253	20,348	-
National Center for Advancing Translational Sciences	93.350	Children's Hospital Boston	U01TR002623	170,612	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Boston	R01DK108805	11,353	-
Child Health and Human Development Extramural Research	93.865	Children's Mercy Hospital	R21HD098086	34,539	-
Cancer Cause and Prevention Research	93.393	Children's Research Institute	R01CA212190	10,050	9,000
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Children's Research Institute	R01HD089289	24,870	-
Child Health and Human Development Extramural Research	93.865	Children's Research Institute	R01HD093622	108,232	-
Child Health and Human Development Extramural Research	93.865	Children's Research Institute	R01HD094213	39,577	-
Child Health and Human Development Extramural Research	93.865	Children's Research Institute	R01HD099284	139,270	-
Child Health and Human Development Extramural Research	93.865	Children's Research Institute	U54HD061221	26,378	-
Cardiovascular Diseases Research	93.837	Cincinnati Ch Hosp Medical Ctr	U01HL131003	39,730	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Cincinnati Ch Hosp Medical Ctr	R01AR075857	6,511	-
Allergy and Infectious Diseases Research	93.855	Cincinnati Ch Hosp Medical Ctr	U54AI117804	60,386	-
Child Health and Human Development Extramural Research	93.865	Cincinnati Children's Hosp Med	R01HD076321	44,451	-
Cancer Treatment Research	93.395	City of Hope National Med Ctr	R01CA196854	8,800	8,000
Human Genome Research	93.172	Columbia University	R21HG010165	92,267	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Columbia University	R01HS026493	48,137	-
Mental Health Research Grants	93.242	Columbia University	R01MH95797	31,399	-
Cancer Treatment Research	93.395	Columbia University	R01CA201788	26,400	24,000
Cancer Centers Support Grants	93.397	Columbia University	U54CA163004	76,656	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Columbia University	R01DK119266	163,748	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Columbia University	R01NS110826	28,069	-
Biomedical Research and Research Training	93.859	Columbia University	R01GM120609	28,775	-
Strengthening the Public Health System in US-affiliated Pacific Islands (PPHF)	93.874	Columbia University	R01NR17206	140,947	-
Child Health and Human Development Extramural Research	93.865	Columbia University	R01HD086045	107,680	-
Medical Library Assistance	93.879	Columbia University	R01LM012895	437,062	-
Child Health and Human Development Extramural Research	93.865	Connecticut Children's Medical Center	R03HD101795	9,943	-
Nursing Research	93.361	Dana-Farber Cancer Institute	R01NR016720	92,387	-
Cancer Detection and Prevention Research	93.394	Dana-Farber Cancer Institute	R01CA214912	81,449	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Dana-Farber Cancer Institute	R01NS091620	33,336	-
Mental Health Research Grants	93.242	Diagnostic Driving, Inc	R43MH122035	13,547	-
Oral Diseases and Disorders Research	93.121	Drexel University	R21DE029567	3,479	-
Trans-NIH Research Support	93.310	Drexel University	UG3OD023342	203,700	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Drexel University	R01NS110898	12,416	-
Aging Research	93.866	Drexel University	R21AG063029	45,440	-
IPPEPP Trial	93.RD	Duke Clinical Res Institute	HHSN275201800003I	20,071	-
Blood Diseases and Resources Research	93.839	Duke University	R01HL151730	58,597	-
Allergy and Infectious Diseases Research	93.855	Duke University	R01AI139032	233,071	-
Child Health and Human Development Extramural Research	93.865	Duke University	R01HD081044	(19,607)	-

The accompanying notes are an integral part of these financial statements.

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2021

Grantor Agency and Department	Assistance Listing Number	Pass-Through Entity	Pass-Through ID Numbers	Total Expenditures ($)	Amount Provided To Subrecipients ($)
Research and Development Cluster, continued					
Child Health and Human Development Extramural Research	93.865	Dupont	R01HD091251	439	-
Mental Health Research Grants	93.242	Emory University	R34MH116805	93,981	-
Lung Diseases Research	93.838	Emory University	UG3HL148560	53,987	-
Cardiovascular Diseases Research	93.837	Etiometry Inc.	R44HL117340	26,832	-
Mental Health Research Grants	93.242	Floreo Technology, LLC	R42MH115539	157,541	17,910
Child Health and Human Development Extramural Research	93.865	Florida State University	R01HD093055	35,706	-
Heart and Vascular Diseases Research	93.837	Four Points Technology, LLC	OT2OD027852	996,520	996,520
Cancer Cause and Prevention Research	93.393	Fox Chase Cancer Center	R01CA138835	29,590	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Fox Chase Cancer Center	R01DK104176	173,071	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Fred Hutchinson Cancer Res Ctr	UM1CA154967	85,841	-
Cancer Cause and Prevention Research	93.393	Fred Hutchinson Cancer Res Ctr	R01CA211996	63,450	44,400
Cardiovascular Diseases Research	93.837	Functional Fluidics	R43HL145898	13,326	-
Mental Health Research Grants	93.242	Geisinger Clinic	R01MH107431	687	-
Lung Diseases Research	93.838	George Washington University	R01HL098354	19,411	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	U01DK061230	43,670	-
Allergy and Infectious Diseases Research	93.855	George Washington University	R01AI123433	106,745	-
Research Related to Deafness and Communication Disorders	93.173	Georgetown University	R01DC016902	6,232	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Harvard Pilgrim Health Care, Inc.	R01DK120598	163,938	-
Enhance Safety of Children Affected by Substance Abuse	93.087	Health Federation of Philadelphia	90CU0104	154,827	-
Mental Health Research Grants	93.242	Hektoen Institute for Medical Research	R01MH104106	40,181	-
Mental Health Research Grants	93.242	Hektoen Institute for Medical Research	R01MH114753	117,967	-
Lung Diseases Research	93.838	Henry Ford Health System	R01HL141845	62,427	-
Lung Diseases Research	93.838	IllExcor Therapeutics LLC	R43HL156334	9,383	-
Blood Diseases and Resources Research	93.839	IllExcor Therapeutics LLC	R43HL150961	30,047	-
Blood Diseases and Resources Research	93.839	IllExcor Therapeutics LLC	R43HL154864	45,691	-
Cancer Centers Support Grants	93.397	Indiana Univ Indianapolis	U54CA196519	80,354	-
Child Health and Human Development Extramural Research	93.865	Innovation Design Labs	R43HD098958	16,806	-
Food Safety Grants	93.103	Institute for Advanced Clinical Trials for Childrer	U18FD006297	3,120	-
Blood Diseases and Resources Research	93.839	Invenux, LLC	R43HL139173	(153)	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Johns Hopkins University	R18HS025642	151,528	-
Mental Health Research Grants	93.242	Johns Hopkins University	R01MH113215	38,355	-
Drug Abuse and Addiction Research Program	93.279	Johns Hopkins University	R01DA043089	79,938	-
Cardiovascular Diseases Research	93.837	Johns Hopkins University	U34HL148480	6,112	-
Lung Diseases Research	93.838	Johns Hopkins University	U01HL126088	48,270	20,171
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Johns Hopkins University	R01DK115648	195,050	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	UM1AI068632	33,796	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	UM2AI130836	317,352	-
Child Health and Human Development Extramural Research	93.865	Johns Hopkins University	R01HD097692	111,926	-
Child Health and Human Development Extramural Research	93.865	Johns Hopkins University	R03HD101336	6,339	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Kennedy Kreiger Institute	K12NS098428	1,927	-
Lung Diseases Research	93.838	Kitware, Inc	R43HL147747	74,964	
Biomedical Research Pediatric Match APEC1621B	93.RD	Leidos Biomedical	N01CO2008-00001	788	788
NCI Cancer Data Service	93.RD	Leidos Biomedical	75N91019D00024	480,826	-
Develop Recombinant AV Vectors	93.RD	Leidos Biomedical	HHSN261200800001E	24,201	-
Trans-NIH Research Support	93.310	Massachusetts General Hospital	UG3OD023253	136,103	-
Cancer Cause and Prevention Research	93.393	Massachusetts General Hospital	R01CA245145	308,136	-
Blood Diseases and Resources Research	93.839	Massachusetts General Hospital	R01HL141366	88,627	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	R01AI127597	87,373	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mayo Clinic	U54NS115198	245,103	-
Cancer Treatment Research	93.395	Medical College of Wisconsin	U24CA76518	12,125	-
Blood Diseases and Resources Research	93.839	Medical College of Wisconsin	U01HL143477	35,506	-
Child Health and Human Development Extramural Research	93.865	Medical College of Wisconsin	R01HD091302	46,638	-
Food Safety Grants	93.103	Medical Device Innovation Consortium	U01FD006292	604,483	345,712
Minority Health and Health Disparities Research	93.307	Medical University of South Carolina	R01MD016012	117,725	-
National Center for Advancing Translational Sciences	93.350	Medical University of South Carolina	U01TR002626	159,415	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Memorial Sloan-Kettering	U24CA220457	157,962	-
Allergy and Infectious Diseases Research	93.855	Michigan State University	U01AI126610	17,601	-
Child Health and Human Development Extramural Research	93.865	Minnesota Health Solutions	R34HD097762	25,754	-
Child Health and Human Development Extramural Research	93.865	Minnesota Health Solutions	R44HD085660	33,396	-
Child Health and Human Development Extramural Research	93.865	Minnesota Health Solutions	R44HD100278	41,542	-
Child Health and Human Development Extramural Research	93.865	Minnesota Health Solutions	R44HD103550	59,981	-

The accompanying notes are an integral part of these financial statements.

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2021

Grantor Agency and Department	Assistance Listing Number	Pass-Through Entity	Pass-Through ID Numbers	Total Expenditures ($)	Amount Provided To Subrecipients ($)
Research and Development Cluster, continued					
Research Related to Deafness and Communication Disorders	93.173	Monell Chemical Senses Center	R01DC011287	202,111	-
Child Health and Human Development Extramural Research	93.865	Monell Chemical Senses Center	R03HD094908	1,344	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Mount Sinai School of Med	U01DK119200	42,379	-
Cardiovascular Diseases Research	93.837	Nationwide Children's Hospital	U34HL144360	311	-
Child Health and Human Development Extramural Research	93.865	Nationwide Children's Hospital	R01HD091347	33,546	-
Child Health and Human Development Extramural Research	93.865	Nationwide Children's Hospital	R01HD095976	128,323	-
Child Health and Human Development Extramural Research	93.865	Nemours Biomedical Research	R01HD092847	14,066	-
Cardiovascular Diseases Research	93.837	New England Research Institute	U24HL135691	25,652	14,246
Pumps for Kids, Infants and Neonates (Pumpkin) Clinical Trial	93.RD	New England Research Institute	HHSN268201200001I	4,917	-
Mental Health Research Grants	93.242	New York University School of Medicine	R01MH119114	40,146	-
Cancer Treatment Research	93.395	New York University School of Medicine	R01CA140729	170,892	-
Trans-NIH Research Support	93.310	Northwestern University	U24OD023319	143,511	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Northwestern University	R01NS096746	56,773	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Northwestern University	U54NS108874	138,607	-
Child Health and Human Development Extramural Research	93.865	Northwestern University	R01HD087363	131,699	-
Blood Diseases and Resources Research	93.839	Ohio State University Res Fdn	R01HL136652	74,428	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Old Dominion Univ Res Fdn	R15CA115464	3,971	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	OncoSynergy, Inc	R41NS115249	69,984	-
Child Health and Human Development Extramural Research	93.865	Orlando Health	R01NS057676	22,185	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Pennsylvania State University	R24DK106766	154,770	-
Allergy and Infectious Diseases Research	93.855	Pennsylvania State University	R21AI140443	8,840	-
Medical Library Assistance	93.879	Phrase Health Inc	R41LM013317	27,598	-
Allergy and Infectious Diseases Research	93.855	Progenra Inc	R44AI109880	(34,103)	-
Child Health and Human Development Extramural Research	93.865	Radiant Creative Group, LLC	R42HD087021	154,021	19,168
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Regents of the UCLA	U01CA233074	291,235	-
Cancer Treatment Research	93.395	Regents of the UCLA	R01CA222695	147,897	-
Cancer Biology Research	93.396	Regents of the UCLA	R01CA220238	321,941	-
Allergy and Infectious Diseases Research	93.855	Regents of the UCLA	UM1AI106716	15,632	-
Child Health and Human Development Extramural Research	93.865	Regents of University of Colorado Denver	R24HD98415	140,343	-
Cancer Treatment Research	93.395	Sarcoma Foundation of America, Inc	U01CA236220	94,463	-
Oral Diseases and Disorders Research	93.121	Seattle Children's Hospital	U01DE025862	(29)	-
Cardiovascular Diseases Research	93.837	Seattle Children's Hospital	R01HL134321	(1,836)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Seattle Children's Hospital	R01NS101029	42,680	-
Cancer Detection and Prevention Research	93.394	St Jude Medical Center	R01CA193478	108,359	99,500
Biomedical Research and Research Training	93.859	St Jude Medical Center	P50GM115279	865	-
Child Health and Human Development Extramural Research	93.865	Stanford University	R01HD099197	178,985	-
Child Health and Human Development Extramural Research	93.865	Stanford University	R01HD84819	11,968	-
Alcohol Research Programs	93.273	SUNY Downstate Medical Center	U10AA008401	209,657	-
Food Safety Grants	93.103	Temple University	U01FD006978	50,169	-
Cardiovascular Diseases Research	93.837	Temple University	R01HL092910	28,320	-
Blood Diseases and Resources Research	93.839	Temple University	R01HL118526	37,919	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Temple University	R01DK121159	7,019	-
Pathology Studies	93.RD	The Emmes Corporation	HHSN26320170001	20,607	-
COVID-19 Multisystem Inflammatory Syndrome in Children (MIS-C) Pilot Project	93.RD	The Emmes Corporation	HHSN275201700002C	753,048	-
Cancer Detection and Diagnosis Research	93.394	The University of Texas	R01CA235756	24,796	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Thomas Jefferson University	R01DK118964	221,076	-
Allergy and Infectious Diseases Research	93.855	Thomas Jefferson University	R01AI123538	7,501	-
Biomedical Research and Research Training	93.859	Thomas Jefferson University	T32GM008562	192,094	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Transonic Systems, Inc.	R44HL136008	254,978	-
Lung Diseases Research	93.838	Trustees of Indiana University	R01HL148247	91,009	-
Arthritis, Musculoskeletal, and Skin Diseases Research	93.846	Tulane University	R01AR069055	9,181	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Tulane University	R01DK107566	85,637	-
Child Health and Human Development Extramural Research	93.865	Univ of Alabama at Birmingham	R01HD095248	16,325	-
Child Health and Human Development Extramural Research	93.865	Univ of Alabama at Birmingham	U54HD061222	42,345	-
Arthritis, Musculoskeletal, and Skin Diseases Research	93.846	Univ of Maryland, Baltimore	R01AR072713	93,350	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Univ of Virginia Health System	R01DK122586	740,695	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Univ of Virginia Health System	K23NS116225	13,641	-
Blood Diseases and Resources Research	93.839	Univ Texas Huston Hth Sci Ctr	R01HL139553	40,298	-
Child Health and Human Development Extramural Research	93.865	Univ Texas Huston Hth Sci Ctr	R21HD097347	62,093	-
Lung Diseases Research	93.838	University of Arizona	UG3HL147016	41,238	-

The accompanying notes are an integral part of these financial statements.

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2021

Grantor Agency and Department	Assistance Listing Number	Pass-Through Entity	Pass-Through ID Numbers	Total Expenditures ($)	Amount Provided To Subrecipients ($)
Research and Development Cluster, continued					
Mental Health Research Grants	93.242	University of California	R01MH109166	262,820	-
Mental Health Research Grants	93.242	University of California	R01MH121462	98,122	-
Nursing Research	93.361	University of California	R01CA202261	130,615	-
Cancer Treatment Research	93.395	University of California	R01CA201788	4,400	4,000
Cardiovascular Diseases Research	93.837	University of California	R01HL146141	249,185	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of California	R01DK120886	92,919	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California	R01NS104322	6,221	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California	U01NS092764	42,153	-
Allergy and Infectious Diseases Research	93.855	University of California	U54AI082973	32,636	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	University of Colorado Denver	U01CA232486	253,849	-
Cardiovascular Diseases Research	93.837	University of Colorado Denver	R01HL141278	126,041	-
Lung Diseases Research	93.838	University of Colorado Denver	U01HL121518	16,619	-
Child Health and Human Development Extramural Research	93.865	University of Colorado Denver	K23HD083359	2,146	-
Food Safety Grants	93.103	University of Florida	R01FD005407	4,214	-
Research on Healthcare Costs, Quality and Outcomes	93.226	University of Florida	U18HS025298	40,167	-
Arthritis, Musculoskeletal, and Skin Diseases Research	93.846	University of Florida	R01AR056973	32,887	-
Alcohol Research Programs	93.273	University of Iowa	R01AA024486	31,777	-
Blood Diseases and Resources Research	93.839	University of Iowa	UG3HL143204	162,697	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Iowa	U01NS055903	221,951	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Kentucky	R01NS112693	20,419	-
Cardiovascular Diseases Research	93.837	University of Maryland	U24HL134763	187,471	-
Arthritis, Musculoskeletal, and Skin Diseases Research	93.846	University of Maryland	R01AR056837	72,140	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Massachusetts	R21NS107924	862	-
Research on Healthcare Costs, Quality and Outcomes	93.226	University of Michigan	R01HS024953	18,121	-
Lung Diseases Research	93.838	University of Michigan	R01HL147261	29,970	-
Lung Diseases Research	93.838	University of Michigan	R01HL149910	74,499	-
Arthritis, Musculoskeletal, and Skin Diseases Research	93.846	University of Michigan	R01AR074079	63,565	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Michigan	U54DK083912	13,220	-
Mental Health Research Grants	93.242	University of Minnesota	R01MH116961	15,687	-
Allergy and Infectious Diseases Research	93.855	University of Minnesota	R21AI139790	2,984	-
Cardiovascular Diseases Research	93.837	University of North Carolina	OT3HL147154	344,438	-
Child Health and Human Development Extramural Research	93.865	University of North Carolina	R01HD055741	53,955	-
Child Health and Human Development Extramural Research	93.865	University of North Carolina	U19HD089881	478,125	-
Child Health and Human Development Extramural Research	93.865	University of North Carolina	U24HD089880	132,003	-
Child Health and Human Development Extramural Research	93.865	University of Oklahoma	R01HD074579	23,885	-
Oral Diseases and Disorders Research	93.121	University of Pennsylvania	R01DE024749	48,714	-
Oral Diseases and Disorders Research	93.121	University of Pennsylvania	R21DE028417	29,513	-
Human Genome Research	93.172	University of Pennsylvania	R01HG010067	84,736	-
Research on Healthcare Costs, Quality and Outcomes	93.226	University of Pennsylvania	R18HS026862	8,397	-
Mental Health Research Grants	93.242	University of Pennsylvania	P50MH113840	8,009	-
Mental Health Research Grants	93.242	University of Pennsylvania	R01MH098742	531,697	-
Mental Health Research Grants	93.242	University of Pennsylvania	R01MH117807	158,041	-
Mental Health Research Grants	93.242	University of Pennsylvania	R01MH118369	89,170	-
Mental Health Research Grants	93.242	University of Pennsylvania	R01MH119185	106,502	-
Mental Health Research Grants	93.242	University of Pennsylvania	R01MH119219	20,578	-
Mental Health Research Grants	93.242	University of Pennsylvania	R01MH126773	76,065	-
Mental Health Research Grants	93.242	University of Pennsylvania	R21MH120739	20,578	-
Mental Health Research Grants	93.242	University of Pennsylvania	U01MH107276	111,646	-
Alcohol Research Programs	93.273	University of Pennsylvania	R01AA024941	38,023	-
Drug Abuse and Addiction Research Program	93.279	University of Pennsylvania	R01DA049514	24,819	-
Minority Health and Health Disparities Research	93.307	University of Pennsylvania	R01MD011518	1,083	-
Minority Health and Health Disparities Research	93.307	University of Pennsylvania	R01MD011679	130,753	-
Minority Health and Health Disparities Research	93.307	University of Pennsylvania	R01MD016029	30,514	-
Trans-NIH Research Support	93.310	University of Pennsylvania	U01DK127405	111,601	-
National Center for Advancing Translational Sciences	93.350	University of Pennsylvania	KL2TR001879	421,824	-
National Center for Advancing Translational Sciences	93.350	University of Pennsylvania	UL1TR001878	2,768,939	12,129
Research Infrastructure Programs	93.351	University of Pennsylvania	P40OD010939	65,856	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	University of Pennsylvania	P01CA214278	345,324	-
Nursing Research	93.361	University of Pennsylvania	R01NR014784	20,052	-
Nursing Research	93.361	University of Pennsylvania	R01NR015639	116,608	-

The accompanying notes are an integral part of these financial statements.

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2021

Grantor Agency and Department	Assistance Listing Number	Pass-Through Entity	Pass-Through ID Numbers	Total Expenditures ($)	Amount Provided To Subrecipients ($)
Research and Development Cluster, continued					
Nursing Research	93.361	University of Pennsylvania	R01NR018425	172,027	-
Cancer Cause and Prevention Research	93.393	University of Pennsylvania	R01CA206058	48,542	-
Cancer Cause and Prevention Research	93.393	University of Pennsylvania	R01CA215518	17,256	-
Cancer Cause and Prevention Research	93.393	University of Pennsylvania	UE5CA246744	53,388	-
Cancer Treatment Research	93.395	University of Pennsylvania	R01CA219006	152,842	-
Cancer Treatment Research	93.395	University of Pennsylvania	R01CA219871	86,821	-
Cancer Centers Support Grants	93.397	University of Pennsylvania	P30CA016520	530,531	-
Cancer Centers Support Grants	93.397	University of Pennsylvania	P30CA16520	136,210	-
Cancer Research Manpower	93.398	University of Pennsylvania	K12CA076931	393,152	-
Cancer Research Manpower	93.399	University of Pennsylvania	R01CA226888	8,899	-
Cardiovascular Diseases Research	93.837	University of Pennsylvania	R01HL073021	27,814	-
Cardiovascular Diseases Research	93.837	University of Pennsylvania	R01HL135090	(320)	-
Cardiovascular Diseases Research	93.837	University of Pennsylvania	R01HL153224	62,320	-
Cardiovascular Diseases Research	93.837	University of Pennsylvania	U01HL129998	120,548	-
Lung Diseases Research	93.838	University of Pennsylvania	K23HL146970	6,913	-
Lung Diseases Research	93.838	University of Pennsylvania	R01HL143364	68,092	-
Lung Diseases Research	93.838	University of Pennsylvania	R01HL150147	353,218	-
Lung Diseases Research	93.838	University of Pennsylvania	UH3HL141736	36,460	-
Blood Diseases and Resources Research	93.839	University of Pennsylvania	P01HL146373	447,246	-
Blood Diseases and Resources Research	93.839	University of Pennsylvania	R01HL091724	18,110	-
Blood Diseases and Resources Research	93.839	University of Pennsylvania	R01HL142122	163,733	-
Blood Diseases and Resources Research	93.839	University of Pennsylvania	R01HL142976	39,567	-
Blood Diseases and Resources Research	93.839	University of Pennsylvania	U24HD095254	13,909	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pennsylvania	P30AR069619	17,829	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pennsylvania	R01AR066098	78	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pennsylvania	R01AR069062	9,853	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pennsylvania	R01AR070873	130,698	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pennsylvania	R01AR071975	13,989	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pennsylvania	R01AR075418	86,202	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pennsylvania	R01AR076392	25,772	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pennsylvania	R01DK070869	34,987	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pennsylvania	R01DK106243	18,310	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pennsylvania	R01DK114054	68,645	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pennsylvania	R01DK117488	48,173	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pennsylvania	R01DK118431	37,503	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pennsylvania	R21DK117297	53,606	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pennsylvania	R21EY031877	40,237	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pennsylvania	U01DK100846	56	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pennsylvania	U01DK103225	1,218	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pennsylvania	U01DK106892	24,714	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pennsylvania	U24DK060990	10,225	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pennsylvania	UH3DK122644	257,562	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pennsylvania	UM1DK126194	239,805	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pennsylvania	K08NS114106	14,016	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pennsylvania	R01NS060653	32,694	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pennsylvania	R01NS094705	1,664	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pennsylvania	R01NS097549	280,480	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pennsylvania	R01NS100949	176	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pennsylvania	R01NS102731	213,932	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pennsylvania	R21NS116315	51,561	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pennsylvania	U01NS114143	344,796	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pennsylvania	U24NS107199	19,760	-
Allergy and Infectious Diseases Research	93.855	University of Pennsylvania	P30AI045008	270,936	-
Allergy and Infectious Diseases Research	93.855	University of Pennsylvania	R01AI1139123	46,204	-
Allergy and Infectious Diseases Research	93.855	University of Pennsylvania	R01AI123539	300,316	-
Allergy and Infectious Diseases Research	93.855	University of Pennsylvania	R01AI130115	86,539	-
Allergy and Infectious Diseases Research	93.855	University of Pennsylvania	R01AI137062	64,959	-
Allergy and Infectious Diseases Research	93.855	University of Pennsylvania	R21AI138564	215	-
Biomedical Research and Research Training	93.859	University of Pennsylvania	K12GM081259	22,502	-
Biomedical Research and Research Training	93.859	University of Pennsylvania	R01GM123019	152,591	-

The accompanying notes are an integral part of these financial statements.

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2021

Grantor Agency and Department	Assistance Listing Number	Pass-Through Entity	Pass-Through ID Numbers	Total Expenditures ($)	Amount Provided To Subrecipients ($)
Research and Development Cluster, continued					
Biomedical Research and Research Training	93.859	University of Pennsylvania	R01GM124111	47,607	-
Child Health and Human Development Extramural Research	93.865	University of Pennsylvania	K12HD085848	11,095	-
Child Health and Human Development Extramural Research	93.865	University of Pennsylvania	R01HD089390	35,839	-
Child Health and Human Development Extramural Research	93.865	University of Pennsylvania	R01HD097686	234,055	-
Child Health and Human Development Extramural Research	93.865	University of Pennsylvania	R21HD088941	355	-
Child Health and Human Development Extramural Research	93.865	University of Pennsylvania	R21HD091330	(3,356)	-
Child Health and Human Development Extramural Research	93.865	University of Pennsylvania	R21HD093369	(1,304)	-
Child Health and Human Development Extramural Research	93.865	University of Pennsylvania	U01HD087180	5,400	-
Child Health and Human Development Extramural Research	93.865	University of Pennsylvania	U10HD068244	217,003	-
Child Health and Human Development Extramural Research	93.865	University of Pennsylvania	R01HD098269A1	15,311	-
Aging Research	93.866	University of Pennsylvania	R56AG062665	5,278	-
Aging Research	93.866	University of Pennsylvania	U01AG032984	25,025	-
Vision Research	93.867	University of Pennsylvania	R21EY029776	59,215	-
Medical Library Assistance	93.879	University of Pennsylvania	R01LM013437	13,554	-
National Center on Sleep Disorders Research	93.233	University of Pennsylvania- Dept of Genetics	R01HL143790	500,731	-
Mental Health Research Grants	93.242	University of Pennsylvania- Dept of Psychiatry	P30MH097488	172,700	-
Mental Health Research Grants	93.242	University of Pittsburgh	P50MH115838	16,547	-
Mental Health Research Grants	93.242	University of Pittsburgh	R01MH100155	19,627	-
Cardiovascular Diseases Research	93.837	University of Pittsburgh	R01HL128818	870	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pittsburgh	R01DK109365	44,072	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pittsburgh	R01DK122798	248,309	-
Biomedical Research and Research Training	93.859	University of Pittsburgh	R01GM110424	173	-
Mental Health Research Grants	93.242	University of Richmond	R15MH117628	20,268	-
Research Infrastructure Programs	93.351	University of South Alabama	R01OD010944	106,225	-
Cancer Detection and Diagnosis Research	93.394	University of Southern California	R01CA197903	94,378	-
Biomedical Research and Research Training	93.859	University of Southern California	R01GM124532	38,089	-
Oral Diseases and Disorders Research	93.121	University of Utah, The	R01DE027493	11,171	-
Cardiovascular Diseases Research	93.837	University of Utah, The	U24HL135691	1,590	-
Nursing Research	93.361	University of Washington	R21NR017471	1,628	-
Child Health and Human Development Extramural Research	93.865	University of Washington	R01HD088125	84,241	-
Lung Diseases Research	93.838	UPenn Cardiovascular Institute	U01HL148857	57,603	-
Cancer Cause and Prevention Research	93.393	Vanderbilt University	R01CA225005	33,920	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University	UM1AI148452	194,153	-
Biomedical Research and Research Training	93.859	Vanderbilt University	R01GM130791	92,690	-
Child Health and Human Development Extramural Research	93.865	Vanderbilt University	R21HD097992	18,498	-
International Research and Research Training	93.989	Vanderbilt University	R21TW011327	3,582	-
Blood Diseases and Resources Research	93.839	Vascular Vision Pharmaceutical Company	R41HL147737	71,437	-
Blood Diseases and Resources Research	93.839	Villanova University	R15HL133880	20,186	-
Minority Health and Health Disparities Research	93.307	Virginia Commonwealth University	R01MD009124	(579)	-
Blood Diseases and Resources Research	93.839	Virginia Commonwealth University	R61HL156158	108	-
Research Related to Deafness and Communication Disorders	93.173	Washington Univ in St. Louis	U01DC018942	28,583	-
Mental Health Research Grants	93.242	Washington Univ in St. Louis	R01MH118362	121,858	-
Cancer Detection and Prevention Research	93.394	Washington Univ in St. Louis	R01CA211711	46,779	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Washington Univ in St. Louis	R01DK124274	18,295	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Washington Univ in St. Louis	R21NS116574	26,228	-
Allergy and Infectious Diseases Research	93.855	Washington Univ in St. Louis	R21AI154370	102,749	-
Child Health and Human Development Extramural Research	93.865	Wayne State University	U19HD089875	170,666	-
Cancer Cause and Prevention Research	93.393	Weill Medical College of Cornell University	R01CA244500	9,385	-
Lung Diseases Research	93.838	Wistar Institute, The	R01HL147472	136,781	-
Minority Health and Health Disparities Research	93.307	Yale University	R01MD014853	77,451	-
Total National Institutes of Health - Pass Through				34,485,036	1,687,340
Total National Institutes of Health				**189,851,663**	**56,643,977**

The accompanying notes are an integral part of these financial statements.

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2021

Grantor Agency and Department	Assistance Listing Number	Pass-Through Entity	Pass-Through ID Numbers	Total Expenditures ($)	Amount Provided To Subrecipients ($)
Research and Development Cluster, continued					
Food and Drug Administration					
Direct Grants and Contracts;					
Food and Drug Administration-Research	93.103			1,776,111	702,073
Incidence and Outcomes of Human Adenovirus Infection	93.RD			61,353	-
Polyethylene Glycol Safety in Children	93.RD			44,313	-
Total Food and Drug Administration - Direct				1,881,777	702,073
Total Food and Drug Administration				**1,881,777**	**702,073**
Health Resources and Services Administration					
Direct Grants and Contracts:					
Environmental Health	93.113			219,324	-
Maternal and Child Health Federal Consolidated Programs	93.110			2,765,952	547,116
Emergency Medical Services for Children	93.127			31,832	-
Total Health Resource and Services Administration - Direct				3,017,109	547,116
Pass Through:					
Maternal and Child Health Federal Consolidated Programs	93.110	American Academy of Pediatrics	U5DMC39344	38,871	-
Maternal and Child Health Federal Consolidated Programs	93.110	American Academy of Pediatrics	UA6MC15585	1,860	-
Environmental Health	93.113	Johns Hopkins University	R01ES026961	29,745	-
Sickle Cell Treatment Demonstration Program	93.365	Johns Hopkins University	U1EMC27864	89,248	-
Maternal and Child Health Federal Consolidated Programs	93.110	Massachusetts General Hospital	UA3MC11054	12,342	-
Maternal and Child Health Federal Consolidated Programs	93.110	Regents of the UCLA	UA6MC32492	22,463	-
Environmental Health	93.113	University of Pennsylvania	R21ES031243	16,328	-
Total Health Resource and Services Administration - Pass Through				210,857	-
Total Health Resources and Services Administration				**3,227,966**	**547,116**
Agency for Healthcare Research & Quality					
Direct Grants and Contracts:					
Research on Healthcare Costs, Quality, and Outcomes	93.226			1,863,092	178,699
Total Agency for Healthcare Research and Quality - Direct				1,863,092	178,699
Total Agency for Healthcare Research & Quality				**1,863,092**	**178,699**
Total U.S. Department of Health and Human Services				**197,748,459**	**58,386,075**
U.S. Department of Defense					
Department of Army, Army Research and Material Command					
Direct Grants and Contracts:					
Military Medical Research and Development	12.420			3,918,403	270,935
Basic Scientific Research	12.431			7,155	2,430
Total United States Department of Army - Direct				3,925,557	273,365
Pass Through:					
Military Medical Research and Development	12.420	Children's Hospital Boston	W81XWH-17-1-0532	13,885	-
Military Medical Research and Development	12.420	Mind Research Network	W81XWH-17-2-005	15,072	-
Military Medical Research and Development	12.420	Moberg Research Inc	W81XWH1920013	20,560	-
Military Medical Research and Development	12.420	New York Univ School of Med	W81XWH-16-0598	(1,524)	-
Basic Scientific Research	12.431	Trustee of Univ Pennsylvania	W911NF2010080	65,033	-
Military Medical Research and Development	12.420	Trustees of Indiana University	W81XWH-19-1-0575	59,450	-
Military Medical Research and Development	12.420	Univ of Alabama at Birmingham	W81XWH17-0037	92,300	-
Military Medical Research and Development	12.420	University of Michigan	W81XWHBAA141	3,309	-
Total United States Department of Army - Pass Through				268,086	-

The accompanying notes are an integral part of these financial statements.

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2021

Grantor Agency and Department	Assistance Listing Number	Pass-Through Entity	Pass-Through ID Numbers	Total Expenditures ($)	Amount Provided To Subrecipients ($)
Research and Development Cluster, continued					
Total Department of Army, Army Research and Material Command				**4,193,644**	**273,365**
National Aeronautics and Space Administration					
Direct Grants and Contracts:					
Total National Aeronautics and Space Administration	43.003			31,398	-
Total National Aeronautics and Space Administration - Direct				31,398	-
Pass Through:					
Science	43.003	Baylor University	NNX16A069A	69,325	-
Total National Aeronautics and Space Administration - Pass Through				69,325	-
Total National Aeronautics and Space Administration				**100,723**	**-**
Total U.S. Department of Defense				**4,294,367**	**273,365**
Environmental Protection Agency					
Office of Air and Radiation					
Direct Grants and Contracts:					
Surveys, Studies, Research, Investigations, Demonstrations, and Special Purpose Activities Relating to the Clean Air Act	66.034			(2)	-
Total United States Department of Army - Direct				(2)	-
Total Environmental Protection Agency				**(2)**	**-**
National Science Foundation					
Direct Grants and Contracts:					
Engineering Grants	47.041			216,570	-
Computer and Information Science and Engineering	47.070			37,130	-
Social, Behavioral, and Economic Sciences	47.075			2,734	-
Total National Science Foundation - Direct				256,434	-
Pass Through:					
Computer and Information Science and Engineering	47.070	Drexel University	1741306	47,068	-
Social, Behavioral, and Economic Sciences	47.075	University of Pennsylvania	1917608	6,974	-
Total National Science Foundation - Pass Through				54,042	-
Total National Science Foundation				**310,476**	**-**
United States Department of Education					
Direct Grants and Contracts:					
Education Research, Development and Dissemination	84.305			909,752	164,833
Total United States Department of Education-Direct				909,752	164,833
Total United States Department of Education				**909,752**	**164,833**
Total Research and Development Cluster				**203,263,052**	**58,824,273**

The accompanying notes are an integral part of these financial statements.

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2021

Grantor Agency and Department	Assistance Listing Number	Pass-Through Entity	Pass-Through ID Numbers	Total Expenditures ($)	Amount Provided To Subrecipients ($)
Head Start Cluster					
U.S. Department of Health and Human Services					
Administration for Children and Families					
Direct Grants and Contracts:					
Head Start	93.600			1,917,650	101,264
Total Administration for Children and Families - Direct				1,917,650	101,264
Total Administration for Children and Families				**1,917,650**	**101,264**
Total U.S. Department of Health and Human Services				**1,917,650**	**101,264**
Total Head Start Cluster				**1,917,650**	**101,264**
Highway Safety Cluster					
U.S. Department of Transportation					
Pass Through:					
Highway Research and Development Program	20.600	Ohio Department of Public Safety	69A37519300004020OH0	206,195	-
Total US Department of Transportation - Pass Through				206,195	-
Total US Department of Transportation				**206,195**	**-**
Total Highway Safety Cluster				**206,195**	**-**
477 Cluster					
U.S. Department of Health and Human Services					
National Institutes of Health					
Pass Through:					
Cancer Research Manpower	93.558	Philadelphia Works, Inc.	090-016-336-1	164,445	-
Total National Institute of Health-Pass Through				164,445	-
Total National Institutes of Health				**164,445**	**-**
Total U.S. Department of Health and Human Services				**164,445**	**-**
Total 477 Cluster				**164,445**	**-**

The accompanying notes are an integral part of these financial statements.

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2021

Grantor Agency and Department	Assistance Listing Number	Pass-Through Entity	Pass-Through ID Numbers	Total Expenditures ($)	Amount Provided To Subrecipients ($)
Other Federal Awards					
U.S. Department of Health and Human Services					
Center for Disease Control and Prevention					
Pass Through:					
Centers for Disease Control and Prevention Investigations and Technical Assistance	93.283	Minnesota Refugee Health Pgm	U50CK000459	108,090	-
Centers for Disease Control and Prevention Investigations and Technical Assistance	93.283	Regents of the University of Minnesota	NU50CK000495	26,766	-
Subtotal Assistance Listing 93.323				134,856	
Emerging Infections Programs	93.317	Minnesota Refugee Health Pgm	NU50CK000563	668	-
Environmental Public Health and Emergency Response	93.070	PA Department of Health:Environmental Public	SAP #4100078068	20,586	-
Preventive Health and Health Services Block Grant	93.991	PA Department of Health:Preventive Health anc	SAP #4100078068	93,780	-
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)	93.323	Philadelphia Department of Health- Epidemiolog	1820333-02	16,101	-
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)	93.323	Philadelphia Department of Health- Epidemiolog	1820333-03	76,307	-
Subtotal Assistance Listing 93.323				92,408	-
Total Center for Disease Control and Prevention - Pass Through				342,298	-
Total Center for Disease Control and Prevention				**342,298**	-
Health Resource and Service Administration					
Direct Grants and Contracts:					
Poison Control Stabilization and Enhancement Grants	93.253			704,521	-
COVID-19 Provider Relief Fund	93.498			54,274,751	-
Total Health Resource and Services Administration - Direct				54,979,272	-
Pass Through:					
National Bioterrorism Hospital Preparedness Program	93.889	Pennsylvania Department of Health	4100086079	348,157	-
Subtotal Assistance Listing 93.889				348,157	-
Children's Rehabilitation Clinic Services	93.994	Pennsylvania Department of Health	SAP#4100078301	22,409	-
Sickle Cell Contract	93.994	Pennsylvania Department of Health	SAP #4100079945	152,346	46,082
Circle of Care Ryan White Title IV	93.994	Access Matters	204403	35,448	-
Circle of Care Ryan White Title IV	93.994	Access Matters	214403	114,079	-
Circle of Care Ryan White Title IV	93.994	Access Matters	214403COV	5,080	-
Special Child Health & Early Intervention, Child Evaluation Centers 2021	93.994	NJ Department of Health	NJDHSS #DFHS21EVL003	80,817	-
Subtotal Assistance Listing 93.994				410,178	46,082
HIV Emergency Relief Project Grants	93.914	City of Philadelphia	RM0810	134,488	-
HIV Emergency Relief Project Grants	93.914	City of Philadelphia	RM1810	47,717	-
HIV Emergency Relief Project Grants	93.914	City of Philadelphia	RW0650	88,377	-
HIV Emergency Relief Project Grants	93.914	City of Philadelphia	RW1650	30,112	-
HIV Emergency Relief Project Grants	93.914	City of Philadelphia	RW0995	113,749	-
HIV Emergency Relief Project Grants	93.914	City of Philadelphia	RW1995	53,605	-
HIV Emergency Relief Project Grants	93.914	City of Philadelphia	RM0809	149,868	-
Subtotal Assistance Listing 93.914				617,917	-
HIV Prevention Activities Health Department Based	93.940	City of Philadelphia	CP0012	102,096	-
HIV Prevention Activities Health Department Based	93.940	City of Philadelphia	CP1012	63,252	-
HIV Prevention Activities Health Department Based	93.940	City of Philadelphia	CP0043	20,000	10,000
HIV Prevention Activities Health Department Based	93.940	City of Philadelphia	CP1043	6,293	
HIV Prevention Activities Health Department Based	93.940	City of Philadelphia	ST1481	64,936	-
Subtotal Assistance Listing 93.940				256,577	10,000
Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153	Access Matters	204404	8,718	-
Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153	Access Matters	214404	76,933	-
Subtotal Assistance Listing 93.153				85,651	-

The accompanying notes are an integral part of these financial statements.

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2021

Grantor Agency and Department	Assistance Listing Number	Pass-Through Entity	Pass-Through ID Numbers	Total Expenditures ($)	Amount Provided To Subrecipients ($)
Emergency Medical Services for Children	93.127	University of California	U03MC0001	184,410	-
HIV Care Formula Grants	93.917	City of Philadelphia	UAC-DCBPS	65,000	-
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	93.918	City of Philadelphia	1820007-03	77,958	-
Special Projects of National Significance	93.928	Philadelphia Fight	H97HA288940100	2,421	-
Total Health Resources and Services Administration-Pass-Through				2,048,269	56,082
Total Health Resource and Services Administration				**57,027,541**	**56,082**
Office of Population Affairs					
Pass Through:					
Family Planning Services	93.217	Access Matters	214401	174,124	-
Family Planning Services	93.217	Access Matters	203001	30,370	-
Total Office of Population Affairs - Pass Through				204,494	-
Total Office of Population Affairs				**204,494**	**-**
Total U.S. Department of Health and Human Services				**57,574,332**	**56,082**
U.S. Department of Agriculture					
Direct Grants and Contracts:					
Agricultural Research Basic and Applied Research	10.001			66,081	-
Total US Department of Agriculture - Direct				66,081	-
Total US Department of Agriculture				**66,081**	**-**
U.S. Department of Justice					
Direct Grants and Contracts:					
National Institute of Justice Research, Evaluation, and Development Project Grants	16.560			220,902	-
Pass Through:					
National Institute of Justice Research, Evaluation, and Development Project Grants	16.560	Trustee of Univ Pennsylvania	2014-CK-BX-0008	(105)	-
National Institute of Justice Research, Evaluation, and Development Project Grants	16.560	Trustee of Univ Pennsylvania	2017-CK-BX-0016	30,166	-
Subtotal Assistance Listing 15.560				30,061	-
Crime Victim Assistance	16.575	PA Commission on Crime and Delinquency	2017-VF-05-28133	39,164	-
Crime Victim Assistance	16.575	PA Commission on Crime and Delinquency	2018-VF-05-29001	45,426	-
Crime Victim Assistance	16.575	PA Commission on Crime and Delinquency	2019-SS-02-31382	180,484	-
Crime Victim Assistance	16.575	PA Commission on Crime and Delinquency	2018/2019/2020-VF-05-32915	75,190	-
Subtotal Assistance Listing 15.575				340,265	-
Total US Department of Justice - Pass Through				370,325	-
Total US Department of Justice				**591,227**	**-**
U.S. Department of Transportation					
Pass Through:					
Highway Research and Development Program	20.200	University of Pennsylvania	693JJ31750012	11,060	-
Total US Department of Transportation - Pass Through				11,060	-
Total US Department of Transportation				**11,060**	**-**
Total Expenditures of Federal Awards				**263,794,042**	**58,981,619**

The accompanying notes are an integral part of these financial statements.

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Schedule of Expenditures of New Jersey State Financial Assistance Awards
Fiscal Year Ended June 30, 2021

State Grantor/Program and Program Reference Number	Funding #	Expenditures ($)
Department of Health and Senior Services		
Direct Awards		
Newborn Screening and Genetic Services 2021		
NJ:DFHS21NWB004	46.42208025703	$ 53,764
Hemophilia Services 2021		
NJ:DFHS21HEM004	46.42208025710	
	46.42208026031	130,000
Newborn Screening and Genetic Services 2021		
NJ: DFHS21NWB002	46.42208025756	202,970
Special Child Health & Early Intervention, Child Evaluation Centers 2021		
NJ: DFHS21EVL003 and 93.994	46.42208025726	
	46.42208025727	
	46.42208026214	212,675
Total Expenditures of New Jersey State Financial Assistance		$ 599,409

The accompanying notes are an integral part of these financial statements.

1. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards and Schedule of Expenditures of State Awards (the "Schedules") include the Federal and State of New Jersey grant transactions of The Children's Hospital of Philadelphia Foundation and Controlled Affiliates (the "Enterprise") recorded on the cash basis of accounting, which is a comprehensive basis of accounting other than accounting principles generally accepted in the United States of America. Because the Schedules present only a selected portion of the operations of the Enterprise, they are not intended to and do not present the financial position, changes in net assets or cash flows of the Enterprise. The information in these Schedules is presented in accordance with the requirements of *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance), the New Jersey Department of the Treasury State Grant Compliance Supplement.

Negative amounts represent adjustments or credits to amounts reported as expenditures in prior years. The pass-through ID numbers were noted in the Schedule of Federal Awards when available.

2. Department of Health and Human Services Provider Relief Funds

The Enterprise was the recipient of funding under Assistance Listing 93.498, Department of Health and Human Services (HHS) Coronavirus Aid Relief and Economic Security (CARES) Act Provider Relief Funds (PRF). The grant activity presented in the Schedule of Expenditures of Federal awards associated with this Assistance Listing includes all Period 1 funding received between April 1, 2020 and June 30, 2020 as reported to HRSA via the PRF Reporting Portal and includes lost revenues and direct expenditures. The Schedule of Expenditures of Federal Awards includes $54,274,751 of Provider Relief Funds received that have been covered by $2,378,443 of direct expenditures and $51,896,308 of lost revenues (the total eligible amount of lost revenues reported in the PRF reporting portal was $285,716,768).

Business Name	EIN	Payments Received	Lost Revenues	Direct Expenditures
Children's Hospital of Philadelphia	23-1352166	$42,896,367	$40,517,924	$2,378,443
Children's Health Care Associates of NJ, PC	23-3036699	$900,214	$900,214	$0
Children's Health Care Associates, Inc.	22-2785804	$6,536,794	$6,536,794	$0
Children's Surgical Associates, Ltd.	23-2589322	$2,395,613	$2,395,613	$0

Children's Anesthesiology Assoc Ltd	23-2592835	$1,544,000	$1,544,000	$0
Radiology Associates of Children's Hospital, Inc.	23-2665855	$1,763	$1,763	$0
Totals		**$54,274,751**	**$51,896,308**	**$2,378,443**

3. Facilities and Administrative Costs

Expenditures consist of direct costs and indirect costs. The Enterprise applies its predetermined approved facilities and administration rate when charging indirect costs to federal awards rather than the 10% de minimis cost rate as described in Section 200.424 of the Uniform Guidance.

City of Philadelphia Requirements

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
AIDS Activity Coordination Office Award #RM0810; CFDA #93.914
Statement of Program Expenditures and Program Revenues
Year Ended June 30, 2021
Grant Period 03/01/2020 to 02/28/2021
Award Amount: $158,700
Contract Number: 1720676-03
Activity Description: Outpatient Ambulatory Medical Care MAI

Expenditures		
Personnel:		
Salaries	$	107,354
Fringe Benefits		27,134
Total Personnel Expenditures		134,488
Operating:		
Travel		-
Equipment		-
Supplies		-
Printing		-
Subcontract		-
Other		-
Total Operating Expenditures		-
Total Direct Expenditures		134,488
Administration		-
Total Expenditures		134,488
Program Revenue		-
Net AACO Funded Expenditures	$	134,488

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
AIDS Activity Coordination Office Award #RM0809; CFDA #93.914
Statement of Program Expenditures and Program Revenues
Year Ended June 30, 2021
Grant Period 03/01/2020 to 02/28/2021
Award Amount: $187,983
Contract Number: 1720676-03
Activity Description: Care Services Case Management MAI

Expenditures	
Personnel:	
Salaries	$ 119,206
Fringe Benefits	30,662
Total Personnel Expenditures	149,868
Operating:	
Travel	-
Equipment	-
Supplies	-
Printing	-
Subcontract	-
Other	-
Total Operating Expenditures	-
Total Direct Expenditures	149,868
Administration	-
Total Expenditures	149,868
Program Revenue	-
Net AACO Funded Expenditures	$ 149,868

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
AIDS Activity Coordination Office Award #RM1810; CFDA #93.914
Statement of Program Expenditures and Program Revenues
Year Ended June 30, 2021
Grant Period 03/01/2021 to 02/28/2022
Award Amount: $154,400
Contract Number: 2120574
Activity Description: Outpatient Ambulatory Medical Care MAI

Expenditures	
Personnel:	
Salaries	$ 38,253
Fringe Benefits	9,464
Total Personnel Expenditures	47,717
Operating:	
Travel	-
Equipment	-
Supplies	-
Printing	-
Subcontract	-
Other	-
Total Operating Expenditures	-
Total Direct Expenditures	47,717
Administration	-
Total Expenditures	47,717
Program Revenue	-
Net AACO Funded Expenditures	$ 47,717

The Children’s Hospital of Philadelphia Foundation and Controlled Affiliates
AIDS Activity Coordination Office Award #RW0650; CFDA #93.914
Statement of Program Expenditures and Program Revenues
Year Ended June 30, 2021
Grant Period 03/01/2020 to 02/28/2021
Award Amount: $130,543
Contract Number: 1720676-03
Activity Description: Outpatient/Ambulatory Medical Care

Expenditures	
Personnel:	
Salaries	$ 70,342
Fringe Benefits	18,035
Total Personnel Expenditures	88,377
Operating:	
Travel	-
Equipment	-
Supplies	-
Printing	-
Subcontract	-
Other	-
Total Operating Expenditures	-
Total Direct Expenditures	88,377
Administration	-
Total Expenditures	88,377
Program Revenue	-
Net AACO Funded Expenditures	$ 88,377

The Children’s Hospital of Philadelphia Foundation and Controlled Affiliates
AIDS Activity Coordination Office Award #RW1650; CFDA #93.914
Statement of Program Expenditures and Program Revenues
Year Ended June 30, 2021
Grant Period 03/01/2021 to 02/28/2022
Award Amount: $130,543
Contract Number: 2120574
Activity Description: Outpatient/Ambulatory Medical Care

Expenditures	
Personnel:	
Salaries	$ 23,983
Fringe Benefits	6,129
Total Personnel Expenditures	30,112
Operating:	
Travel	-
Equipment	-
Supplies	-
Printing	-
Subcontract	-
Other	-
Total Operating Expenditures	-
Total Direct Expenditures	30,112
Administration	-
Total Expenditures	30,112
Program Revenue	-
Net AACO Funded Expenditures	$ 30,112

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
AIDS Activity Coordination Office Award #RW0995; CFDA #93.914
Statement of Program Expenditures and Program Revenues
Year Ended June 30, 2021
Grant Period 03/01/2020 to 02/28/2021
Award Amount: $171,038
Contract Number: 1720676-03
Activity Description: Care Services Case Management

Expenditures	
Personnel:	
Salaries	$ 89,992
Fringe Benefits	23,757
Total Personnel Expenditures	113,749
Operating:	
Travel	-
Equipment	-
Supplies	-
Printing	-
Subcontract	-
Other	-
Total Operating Expenditures	-
Total Direct Expenditures	113,749
Administration	-
Total Expenditures	113,749
Program Revenue	-
Net AACO Funded Expenditures	$ 113,749

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
AIDS Activity Coordination Office Award #RW1995; CFDA #93.914
Statement of Program Expenditures and Program Revenues
Year Ended June 30, 2021
Grant Period 03/01/2021 to 02/28/2022
Award Amount: $171,038
Contract Number: 2120574
Activity Description: Care Services Case Management

Expenditures	
Personnel:	
Salaries	$ 42,409
Fringe Benefits	11,196
Total Personnel Expenditures	53,605
Operating:	
Travel	-
Equipment	-
Supplies	-
Printing	-
Subcontract	-
Other	-
Total Operating Expenditures	-
Total Direct Expenditures	53,605
Administration	-
Total Expenditures	53,605
Program Revenue	-
Net AACO Funded Expenditures	$ 53,605

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
AIDS Activity Coordination Office Award #CP0012; CFDA #93.940
Statement of Program Expenditures and Program Revenues
Year Ended June 30, 2021
Grant Period 01/01/2020 to 12/31/2021
Award Amount: $128,000
Contract Number: 1820411-03
Activity Description: TAHC- Testing in Adolescent Healthcare Setting

Expenditures	
Personnel:	
Salaries	$ 80,772
Fringe Benefits	21,324
Total Personnel Expenditures	102,096
Operating:	
Travel	-
Equipment	-
Supplies	-
Printing	-
Subcontract	-
Other	-
Total Operating Expenditures	-
Total Direct Expenditures	102,096
Administration	-
Total Expenditures	102,096
Program Revenue	-
Net AACO Funded Expenditures	$ 102,096

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
AIDS Activity Coordination Office Award #CP1012; CFDA #93.940
Statement of Program Expenditures and Program Revenues
Year Ended June 30, 2021
Grant Period 01/01/2021 to 12/31/2021
Award Amount: $128,000
Contract Number: 1820411-03
Activity Description: TAHC- Testing in Adolescent Healthcare Setting

Expenditures		
Personnel:		
Salaries	$	50,041
Fringe Benefits		13,211
Total Personnel Expenditures		63,252
Operating:		
Travel		-
Equipment		-
Supplies		-
Printing		-
Subcontract		-
Other		-
Total Operating Expenditures		-
Total Direct Expenditures		63,252
Administration		-
Total Expenditures		63,252
Program Revenue		-
Net AACO Funded Expenditures	$	63,252

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
AIDS Activity Coordination Office Award #CP1043; CFDA #93.940
Statement of Program Expenditures and Program Revenues
Year Ended June 30, 2021
Grant Period 01/01/2021 to 12/31/2021
Award Amount: $20,000
Contract Number: 1820411-03
Activity Description: Comprehensive HIV Prevention and Surveillance Project

Expenditures	
Personnel:	
Salaries	$ 4,979
Fringe Benefits	1,314
Total Personnel Expenditures	6,293
Operating:	
Travel	-
Equipment	-
Supplies	-
Printing	-
Subcontract	-
Other	-
Total Operating Expenditures	-
Total Direct Expenditures	6,293
Administration	-
Total Expenditures	6,293
Program Revenue	-
Net AACO Funded Expenditures	$ 6,293

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
AIDS Activity Coordination Office Award #CP0043; CFDA #93.940
Statement of Program Expenditures and Program Revenues
Year Ended June 30, 2021
Grant Period 01/01/2020 to 12/31/2020
Award Amount: $20,000
Contract Number: 1820411-03
Activity Description: Comprehensive HIV Prevention and Surveillance Project

Expenditures	
Personnel:	
Salaries	$ 7,911
Fringe Benefits	2,089
Total Personnel Expenditures	10,000
Operating:	
Travel	-
Equipment	-
Supplies	-
Printing	-
Subcontract	10,000
Other	-
Total Operating Expenditures	10,000
Total Direct Expenditures	20,000
Administration	-
Total Expenditures	20,000
Program Revenue	-
Net AACO Funded Expenditures	$ 20,000

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
AIDS Activity Coordination Office Award #ST1481; CFDA #93.940
Statement of Program Expenditures and Program Revenues
Year Ended June 30, 2021
Grant Period 07/01/2020 to 06/30/2021
Award Amount: $65,000
Contract Number: 2020149-01
Activity Description: HIV Navigation Services

Expenditures		
Personnel:		
Salaries	$	51,373
Fringe Benefits		13,563
Total Personnel Expenditures		64,936
Operating:		
Travel		-
Equipment		-
Supplies		-
Printing		-
Subcontract		-
Other		-
Total Operating Expenditures		-
Total Direct Expenditures		64,936
Administration		-
Total Expenditures		64,936
Program Revenue		-
Net AACO Funded Expenditures	$	64,936

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Health Resource and Service Administration Award #UAC-DCBPS; CFDA #93.917
Statement of Program Expenditures and Program Revenues
Year Ended June 30, 2021
Grant Period 07/01/2020 to 6/30/2021
Award Amount: $65,000
Contract Number: UAC DCBPS
Activity Description: Adolescent Initiative Prevention Program PJJSC

Expenditures	
Personnel:	
Salaries	$ 51,423
Fringe Benefits	13,577
Total Personnel Expenditures	65,000
Operating:	
Travel	-
Equipment	-
Supplies	-
Printing	-
Subcontract	-
Other	-
Total Operating Expenditures	-
Total Direct Expenditures	65,000
Administration	-
Total Expenditures	65,000
Program Revenue	-
Net AACO Funded Expenditures	$ 65,000

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Health Resource and Service Administration Award #1820007-03; CFDA #93.918
Statement of Program Expenditures and Program Revenues
Year Ended June 30, 2021
Grant Period 07/1/2020 to 06/30/2021
Award Amount: $75,000
Contract Number: 1820007-03
Activity Description: HIV Early Intervention Program - Title 3

Expenditures	
Personnel:	
Salaries	$ 53,303
Fringe Benefits	12,655
Total Personnel Expenditures	65,958
Operating:	
Travel	-
Equipment	-
Supplies	12,000
Printing	-
Subcontract	-
Other	-
Total Operating Expenditures	-
Total Direct Expenditures	77,958
Administration	-
Total Expenditures	77,958
Program Revenue	-
Net AACO Funded Expenditures	$ 77,958

Reports on Internal Control and Compliance

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

To the Board of Trustees of
The Children's Hospital of Philadelphia Foundation and Controlled Affiliates

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of Children's Hospital of Philadelphia Foundation and Controlled Affiliates (the "Enterprise"), which comprise the consolidated balance sheets as of June 30, 2021, and the related consolidated statements of operations, changes in net assets and of cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated September 30, 2021 which includes an emphasis of matter paragraph as the Enterprise changed its method of accounting for leases in 2021.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Enterprise's internal control over financial reporting ("internal control") as a basis for designing the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Enterprise's internal control. Accordingly, we do not express an opinion on the effectiveness of the Enterprise's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Enterprise's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

PricewaterhouseCoopers LLP, Two Commerce Square, Suite 1800, 2001 Market Street, Philadelphia, PA 19103-7042
T: (267) 330 3000, F: (267) 330 3300, www.pwc.com/us

pwc

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Enterprise's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Philadelphia, Pennsylvania

September 30, 2021

Report of Independent Auditors on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and on Internal Control Over Compliance in Accordance with the Uniform Guidance and *the City of Philadelphia Subrecipient Audit Guide*, which incorporates the guidance from the Uniform Guidance

To the Board of Trustees of
The Children's Hospital of Philadelphia Foundation and Controlled Affiliates

Report on Compliance for Each Major Federal and City of Philadelphia Program

We have audited the Children's Hospital of Philadelphia Foundation and Controlled Affiliates' (the "Enterprise")'s compliance with the types of compliance requirements described in the *OMB Compliance Supplement* and the *City of Philadelphia Subrecipient Audit Guide*, which incorporates the guidance from OMB Uniform Guidance, that could have a direct and material effect on each of the Enterprise's major federal and City of Philadelphia programs for the year ended June 30, 2021. The Enterprise's major federal and City of Philadelphia programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal and City of Philadelphia statutes, regulations and the terms and conditions of its federal and City of Philadelphia awards applicable to its federal and City of Philadelphia programs.

Auditor's Responsibility

Our responsibility is to express an opinion on compliance for each of the Enterprise's major federal and City of Philadelphia programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and the audit requirements of the *City of Philadelphia Subrecipient Audit Guide,* which incorporate the guidance from OMB Uniform Guidance. Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal or city program occurred. An audit includes examining, on a test basis, evidence about the Enterprise's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal and City of Philadelphia program. However, our audit does not provide a legal determination of the Enterprise's compliance.

Opinion on Each Major Federal and* City of Philadelphia *Program

In our opinion, the Enterprise complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal and City of Philadelphia programs for the year ended June 30, 2021.

Report on Internal Control Over Compliance

Management of the Enterprise is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the Enterprise's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal and City of Philadelphia program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal and City of Philadelphia program and to test and report on internal control over compliance in accordance with the Uniform Guidance and the *City of Philadelphia Subrecipient Audit Guide*, which incorporates the guidance from OMB Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the Enterprise's internal control over compliance.

A *deficiency in internal control* over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal or city program on a timely basis. A *material weakness in internal control* over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal or city program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* in *internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal or city program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance and the *City of Philadelphia Subrecipient Audit Guide,* which incorporates the guidance from OMB Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Philadelphia, Pennsylvania

June 30, 2022

Schedule of Findings and Questioned Costs

The Children's Hospital of Philadelphia Foundation and Controlled Affiliates
Schedule of Findings and Questioned Costs
Fiscal Year Ended June 30, 2021

Section I – Summary of Auditor's Results

Consolidated Financial Statements

(i)	Type of auditor's report issued	Unmodified	
(ii)	Internal control over financial reporting :		
	Material weakness(es) identified?	___ yes	X no
	Significant deficiency(ies) identified not considered to be material weaknesses?	___ yes	X none reported
(iii)	Noncompliance material to consolidated financial statements noted?	___ yes	X no

Federal Awards

(iv)	Internal control over major programs :		
	Material weakness(es) identified?	___ yes	X no
	Significant deficiency(ies) identified not considered to be material weaknesses?	___ yes	X none reported
(v)	Type of auditor's report issued on compliance for major programs:	Unmodified	
(vi)	Any audit findings disclosed that are required to be reported in accordance with 2CFR 200.516(a)?	___ yes	X none reported
(vii)	Identification of major programs:		
	Name of Federal Program or Cluster	**Assistance Listing Number**	
	COVID-19 Provider Relief Funds	93.498	
(viii)	Dollar threshold used to distinguish between Type A and Type B programs:	$3,000,000	
(ix)	Auditee qualified as low-risk auditee	X yes	___ no

City Awards

(iv)	Internal control over major programs :		
	Material weakness(es) identified?	___ yes	X no
	Significant deficiency(ies) identified not considered to be material weaknesses?	___ yes	X none reported
(v)	Type of auditor's report issued on compliance for major programs:	Unmodified	
(vi)	Any audit findings disclosed that are required to be reported in accordance with the 2CFR 200.516(a) and the *City of Philadelphia Subrecipient Audit Guide*		X none reported
(vii)	Identification of major programs:		
	Name of City Program	**Assistance Listing Number**	
	AIDS Activities Coordinating Office (AACO)	93.940	
(i)	Dollar threshold used to distinguish between Type A and Type B programs:	$750,000	
(ii)	Auditee qualified as low-risk auditee	X yes	___ no

Section II – Financial Statement Findings

None noted.

Section III – Federal and City Award Findings and Questioned Costs

None noted.

Section III - Federal and City Awards

There are no findings from prior years that require an update in this report.